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1.1 Pathogen detection by the innate immune system 
 
An effective microbial immune response is based on the detection of pathogens by the 
host immune system. In the course of an evolutionary “arms-race”, vertebrates have 
developed two major branches of immunological defense, the innate and adaptive 
immune system (Dawkins et al., 1979). These branches include a subset of humoral 
and cellular immune mechanisms, which can efficiently recognize and clear pathogen 
infection. An integer part of the innate branch is the recognition of distinct pathogenic 
or danger signatures, the pathogen-associated molecular patterns (PAMPs) or 
danger-associated molecular patterns (DAMPs), by pattern recognition receptors 
(PRRs). Recognition of PAMPs or DAMPs is essential to the host organism to 
distinguish self from an invading pathogen or detect a cellular imbalance and to 
consequently activate a downstream signaling cascade (Janeway, 1989). Accordingly, 
pathogens have developed strategies to avoid detection by the host system. Invading 
the host cell and replicating intracellularly enables pathogens to escape detection by 
extracellular immune responses, such as the complement system, phagocytes and 
antibodies (Kumar and Valdivia, 2009). In most cases, an invading pathogen will enter 
the host cell within a vacuolar compartment, as the result of phagocytosis or by 
facilitating their own endocytosis. To prevent lysis by the host cell, pathogens must 
avoid fusion of their compartment with lysosomes. Only a few microbial pathogens can 
replicate directly in the cytosol (Kumar and Valdivia, 2009), as the broad spectrum of 
host cytosolic defense mechanisms enforce the necessity to reside in sheltered 
compartments, generally referred to as pathogen containing vacuoles (PCV) (Case et 
al., 2014; Paciello et al., 2013). The host cytosolic defense system initiates the 
secretion of pro-inflammatory cytokines, chemokines, and the recruitment of effector 
immune cells. In addition, inflammatory host cell death (pyroptosis) can be induced by 
the activation of inflammasome complexes. In general, these mechanisms lead to the 
elimination of the pathogens or infected cells. However, chronic, or erroneous 





1.2 The effector immune response 
 
Detection of PAMPs and DAMPs by PRRs of antigen presenting cells (APCs) leads to 
transcriptional upregulation of genes involved in inflammatory responses (Akira and 
Takeda, 2004; Akira et al., 2006). These genes encode type I interferons, chemokines, 
pro-inflammatory cytokines and proteins that in turn regulate PRR signaling and 
expression. Inflammation is coordinated by the proinflammatory cytokines tumor 
necrosis factor (TNF), interleukin (IL)-1, and IL-6 (Akira et al., 2006). Proinflammatory 
cytokines are regulated on the transcriptional and translational level. However, IL-1β 
has an additional control mechanism. Transcription of IL-1β is initiated by toll-like 
receptor (TLR) signaling, but expression occurs as the 31 kDa precursor protein, Pro-
IL-1β, which is matured by proteolytic cleavage by caspase-1. Caspase-1 activation is 
mediated by the inflammasome complex composed of adaptor molecules, a cytosolic 
PRR and Pro-Caspase-1 (Mariathasan et al., 2006; Martinon et al., 2002). The most 
well characterized inflammasome complex thus far consists of the cytosolic NOD-like 
receptor (NLR) called NLRP3. NLRP3 has a tripartite structure with a pattern sensory 
domain, the C-terminal leucine rich repeat (LRR), a central nucleotide binding (or 
NACHT) domain and an N-terminal pyrin domain (PYD). The PYD recruits the adaptor 
molecule apoptosis-associate speck-like protein containing a caspase recruitment 
domain (ASC). ASC is composed of a PYD and a caspase activation and recruitment 
domain (CARD) domain. The latter engages in homotypical interaction with the CARD 
of caspase 1, facilitating its autoproteolysis and activation. Following the proteolytic 
processing of Pro-IL-1β, the mature 17 kDa cytokine is secreted from the cell, either 
passively by pyroptosis or by active vesicle transport (Agostini et al., 2004; Kanneganti 
et al., 2007; Nickel and Rabouille, 2009). IL-1β can induce the expression of hundreds 
of genes that lead to the recruitment of immune cells (such as T cells and B cells) to 




Inflammasomes are cytosolic signaling complexes initiated by pattern recognition 
receptors and serve as activation platforms for inflammatory caspases, like mouse 
caspase-1 and caspase-11 or human caspase-1, caspase-4 and caspase-5 (Man et 
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al., 2015). Inflammatory caspase activation leads to IL-1β processing and pyroptosis. 
IL-1β is a key regulator of inflammatory responses, thus over-production is associated 
with autoinflammatory syndromes, such as gout and periodic fever syndromes. A 
canonical and the non-canonical pathway can be distinguished. Canonical 
inflammasome complexes consist of a sensor molecule and an adaptor molecule that 
activates caspase 1-mediated downstream signaling. There are two classes of sensor 
molecules: NLRs and AIM2-like receptors (ALRs). Sensor proteins have an effector 
domain such as the CARD, PYD or baculoviral inhibitor of apoptosis (IAP) repeat 
domain for interaction with an adaptor molecule or for direct caspase 1 activation, a 
NACHT domain and a LRR domain. The most common adaptor molecule is ASC. ASC 
is composed of a PYD and a CARD domain. The latter engages in homotypical 
interaction with the CARD of caspase 1. The canonical pathway refers to the 
downstream activation of caspase 1, whereas the non-canonical pathway results in 
processive cleavage of mouse caspase 11 or human caspase 4/5 (Lu and Wu, 2015) 
(see Fig. 1). The canonical pathway is initiated by the sensing of pathogenic ligands 
via receptor molecules of the NLR or pyrin and HIN200 domain-containing (PYHIN ) 
family, whereas in case of the non-canonical pathway caspase 11 (human caspase-
4) is supposed to directly sense bacterial lipopolysaccharides (LPS) (Shi et al., 
2014).Upon entry of gram-negative bacteria, IFN-induced factors are suggested to 
liberate LPS, which can be sensed by components of the non-canonical 
inflammasome that subsequently activate Gasdermin D-mediated pyroptosis or 
cytokine release via the NLRP3- caspase-1-pathway (Kayagaki et al., 2015; Man et 







Figure 1 Canonical and non-canonical inflammasome pathways. The canonical inflammasome 
pathway is activated by a plethora of pathogen or danger signatures. Nek7 (green) is recruited to the 
LRR domain (blue) of NLRP3 and stabilizes inflammasome formation as depicted in the crystal structure 
of NLRP3 NACHT-LRR bound to Nek7 (6NPY). NLRP3 recruits pro-caspase-1 through the adaptor 
protein ASC leading to autoproteolytic activation of pro-caspase-1 (grey + yellow) to caspase-1. 
Caspase-1 processes the pro-inflammatory cytokine pro- IL-1β (bright yellow) to mature IL-1β, which is 
secreted from the cell. Caspase-1 induces pyroptosis by cleaving Gasdermin D (brown). The non-
canonical inflammasome murine caspase-11 or human caspase-4/-5 is activated by LPS of gram-
negative bacteria and cleaves Gasdermin D to induce pyroptosis. Caspase-11 also leads to NLRP3 




1.3.1 NOD-like receptors 
 
Based on the effector function of their N-termini, NLRs can be divided into four 
subfamilies (see Fig. 2): The acidic transactivation domain (NLRA), the baculoviral 
inhibitory repeat-like domain (NLRB), the CARD (NLRC) and the PYD (NLRP) and 
four functional groups: inflammasome assembly, autophagy, signal transduction and 
transcription activation (Motta et al., 2015; Ting et al., 2008). The NLRs perceive a 
plethora of ligands derived from either pathogen (viral RNA, flagellin, peptidoglycan, 
toxins) environmental substances (asbestos, alum, skin irritants, UV radiation) or the 
host cell itself (ATP, uric acid, cholesterol crystals) (Davis et al., 2011). The latter is a 
form of recognition of cellular stress or a homeostatic imbalance of the cell. There are 
eight members of NLRs that can form inflammasomes (NLRP1, NLRP2, NLRP3, 
NLRP6, NLRP7, NLRP12, NLRC4 and NAIP). NLRP1 recognizes anthrax lethal toxin 
and MDP, a peptidoglycan motif common to gram-negative and gram-positive bacteria 
(Kang et al., 2008; Levinsohn et al., 2012). Since it contains a CARD, NLRP1 can 
directly interact with procaspase-1 and form an active inflammasome. NLRC4 lacks 
the pyrin domain and can form two different types of inflammasome complexes. NAIP 
and NLRC4 form an inflammasome complex that recognizes flagellin and components 
of the type III secretion system, making it an indicator of bacterial infection (Amer et 
al., 2006; Franchi et al., 2006; Kofoed and Vance, 2011). NLRC4 can also recruit ASC, 
which leads to the activation of procaspase-1 and processive cleavage of Pro-IL-1β 
and Pro-IL-18 and consecutive pyroptosis (Miao et al., 2010). NLRP6 and NLRP12 
are involved in negative regulation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and NLRP6 is associated with increased susceptibility to 
colitis and colon cancer (Anand et al., 2012; Chen et al., 2011), whereas NLRP12 is 
associated with atopic dermatitis (Macaluso et al., 2007). NLRP7 can recognize 
bacterial lipopeptide (Khare et al., 2012) and mutations in NLRP7 are associated with 
endometrial cancer and testicular seminoma (Ohno et al., 2008; Okada et al., 2004).  
 
However, the most well characterized NLR inflammasome consists of NLRP3. NLRP3 
has been attributed to recognize a vast variety of PAMPs and DAMPS such as alum, 
ATP and uric acid (Davis et al., 2011). This rather promiscuous form of activation has 
challenged scientists trying to discover a common mechanism. Currently, NLRP3 is 
thought to be activated by multiple, mutually non-exclusive upstream danger signals, 
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such as K+, or Cl- efflux or Ca2+ flux, lysosomal damage, mitochondrial dysfunction, 
metabolic changes or Golgi fragmentation (Chen and Chen, 2018; Groß et al., 2016; 
Hornung et al., 2008; Martinon et al., 2006a; Muñoz-Planillo et al., 2013; Wolf et al., 
2016; Zhou et al., 2011). Despite the abundance of data characterizing NLRP3 
activation signals, many pathways are overlapping, interconnected or even conflicting. 
Recently, NIMA-related kinase 7 (Nek7) was demonstrated to specifically interact with 
NLRP3 and stabilize the oligomeric state of the inflammasome, which proved to be 
essential for ASC speck formation and caspase-1 recruitment (He et al., 2016; Sharif 
et al., 2019; Shi et al., 2016). 
 
NLRs are required to sense PAMPS and DAMPS in the cytosol and are thus essential 
to the host immune response. However, NLRs are also involved in other essential 
biological processes. So far, the activation mechanism of many NLRs is poorly 




Figure 2 The NLR subfamily. The cytosolic NOD-like receptors (NLRs) comprise 22 identified intracellular pattern-
recognition receptors in humans. Mammalian NLRs are divided into subfamilies according to their N-terminal 
effector domains. The N-terminal domains are caspase activation and recruitment domain (CARD, yellow), 
transactivator domain (AD, grey), baculoviral inhibitor of apoptosis repeat domain (BIR, red) or pyrin domain 
(PYD, mint green). The c-terminal leucine rich repeat domain (LRR) is indicated in crimson. The NLR subfamilies 
are categorized into subfamilies by the initial of the domain name: NLRA (based on AD), NLRB (based on BIR), 
NLRC (based on CARD) and NLRP (based on PYD). This figure was adapted from InvivoGen (www.invivogen.com). 
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1.4 IL-1β signaling 
 
IL-1β is an important key regulator of the inflammatory response. Upon binding of IL-
1β to the type 1 receptor (IL-1R1), signal transduction depends on three generations 
of mitogen-activated protein kinases (MKKK/MAP3K/MEKKs) and their downstream 
proteins (see Fig. 3). This leads to the activation of transcription factors to orchestrate 
the expression of host defense proteins. Upon binding of IL-1α or IL-1β ligands to IL-
1R1, the co-receptor IL-1 receptor accessory protein (IL-1RAP) associates with IL-
1R1 and activates signal transduction. (Greenfeder et al., 1995). The Toll- and IL-1R–
like (TIR) domains on the cytoplasmic side of IL-1R1 lead to proximity induced 
recruitment of myeloid differentiation primary response gene 88 (MYD88), Toll-
interacting protein (TOLLIP) (Dinarello, 2009) and IL-1 receptor-associated kinase 4 
(IRAK4). They form a stable complex and IL-1 receptor-associated kinases IRAK4, 
IRAK2 and IRAK1 are phosphorylated. This results in the recruitment and 
oligomerization of tumor necrosis factor-associated factor 6 (TRAF6) (Brikos et al., 
2007; Cao et al., 1996a; Cao et al., 1996b). Afterwards, TRAF6 and phosphorylated 
IRAK1 and IRAK2 separate from the complex and localize to the membrane, where 
they form a new complex with TGF-β-activated kinase 1 (TAK1) and TAK1-binding 
proteins TAB1 and TAB2 (Dinarello, 2009). This newly formed TAK1-TAB1-TAB2-
TRAF6 complex moves back to the cytosol, where TRAF6 is ubiquitinated and TAK1 
is phosphorylated (Dinarello, 2009). 
Moving downstream, the signal can follow two different main paths: IKK – IκB – NF-
κB and/or MKK – MAPK/JNK/ERK (Figure 3). In the first path, phosphorylated TAK1 
initiates the degradation of the nuclear factor kappa-B inhibitor (IκB) via inhibitor of 
nuclear factor kappa-B kinase subunit beta (IKKβ) and subsequent activation of 
nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB) that can 
translocate into the nucleus (Oeckinghaus and Ghosh, 2009). NF-κB regulates the 
expression of pro-inflammatory cytokines IL-1,8 and 6, tumor necrosis factor α  (TNF-
α) and Interferon-γ (IFN-γ) (Kojima et al., 1999; Wang et al., 2014). In the second path, 
TAK1 can activate MAPK p38, c-Jun N-terminal kinases (JNK) and extracellular 
signal-regulated kinases (ERK) by binding to MKK proteins (Sato et al., 2005). This 
leads to the activation of transcription factors such as c-Jun, c-Fos, c-Myc and ATF2 
that regulate cell cycle progression, translation and expression of innate effector 
proteins, such as β-defensins (Chang and Karin, 2001; Chiu et al., 1988; Meade and 
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O'Farrelly, 2019). Taken together, IL-1 cytokines secreted by inflammasomes are 
required to regulate an intricate network of inflammatory processes that mediate 
inflammation, pathogen clearance and immune cell recruitment, activation, 




Figure 3 Detailed architecture of IL-1β signaling pathway. Protein-protein interactions of the IL-1β pathway are 
indicated by black lines (protein complex) or black arrows (transient interaction). IL-β binding to IL-1 receptors 
can lead to the activation of two major pathways via the myeloid differentiation primary response gene 88 
(MYD88)-tumor necrosis factor-associated factor 6 (TRAF6) complex. The two major axis lead to the activation 
of master regulators of transcription such as nuclear factor kappa-B kinase NF-κB or c-myc. The transcription 
factors then translocate into the nucleus and lead to the activation of major immune or cell proliferation 




1.5 Macrophages in pathogen clearance 
 
The most versatile antigen presenting cell type and guardian of innate immunity are 
macrophages. An invading pathogen is likely to be detected by macrophages, which 
are highly specialized phagocytes responsible for engulfing cellular debris, foreign 
substances, microbes and dead cells. Blood circulating monocytes that are recruited 
to the site of inflammation, infection or injury can differentiate into two types of 
macrophages, the pro-inflammatory M1 or anti-inflammatory M2 (see Fig. 4) (Mills et 
al., 2000; Nathan et al., 1983). The pro-inflammatory subtype can be evoked by stimuli 
such as the gram-negative bacterial ligand LPS or interferon gamma, whereas the pro-
resolving subtype M2 is regulated by the inhibitors IL-4 and IL-13 (Martinez and 
Gordon, 2014). M2 macrophages have a high phagocytosis capacity and clear 
apoptotic cells and promote wound healing (Ferrante and Leibovich, 2012; Sica and 
Mantovani, 2012). However, in an ongoing injury or inflammation, monocytes exhibit 
a certain plasticity that allows them to switch between pro-inflammatory at the early 
stage of inflammation and pro-resolving during wound healing (Krzyszczyk et al., 
2018). LPS binds to the TLR4 and forms a complex together with myeloid 
differentiation factor 2 (mD2) receptor. Downstream signaling events following this 
receptor complex formation depend on different sets of adaptor proteins. The adaptor 
MyD88 and MyD88 like adapter leads to the activation of NF-κB in early signaling 
events, whereas a later response requires TIR-domain-containing adapter-inducing 
interferon-β (TRIF) and TRIF-related adapter molecule (TRAM), and is followed by the 
late activation of NF-κB and IRF3, and induction of cytokines like IL-1β, chemokines, 
and other transcription factors as well as components of inflammasome (Danis et al., 
1990; Hazuda et al., 1988; Liu et al., 2017). IFN-γ stimulated macrophages show 
increased anti-microbial activity, antigen processing and presentation, upregulation of 
cellular reactive oxygen species (ROS) and nitric oxide synthase (NOS) production 
and induction of autophagy (Gunjan et al., 2018). IFN-γ binds to the IFN-γ receptor 
(IFNGR), which leads to the recruitment of Janus kinases JAK1 and JAK2 to the 
receptor complex. Upon recruitment, autophosphorylated JAK1 phosphorylates JAK2, 
which enables recruitment of signal transducer and activator of transcription 1 
(STAT1). Activated STAT1 translocates to the nucleus and induces the expression of 
interferon stimulated genes (ISGs) and other interferon response factors (Schneider 
et al., 2014). This alerted state of macrophages allows effective clearance of 
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Figure 4 Two phenotypes of macrophage polarization. Macrophages can be differentiated into two phenotypes: 
M1 macrophages (pro-inflammatory, pathogen clearing) are differentiated by IFN-γ or PAMPs and are 
characterized by production of iNOS and pro-inflammatory cytokines such as TNFα and IL-1β. M2 macrophages 
(anti-inflammatory, pro-resolving, apoptotic cell and damaged molecule clearing, wound healing) are induced 
by IL-4 and IL-13 and characterized by anti-inflammatory cytokine IL-10 production. This figure was adapted from 





1.6 IFN-γ - a versatile factor in antimicrobial immunity 
 
IFN-γ is an extremely versatile cytokine in navigating host resistance against 
pathogens leading to the upregulation of numerous antimicrobial processes. One such 
mechanism is that IFN-γ stimulation rapidly facilitates phagolysosomal acidification 
and production of reactive nitrogen/oxygen species in infected macrophages and thus 
enables pathogen clearance (Schroder et al., 2004). At the same time, IFN-γ promotes 
autophagy of intracellular microbes as an effector immune response and induces the 
expression of various lysosomal components, granules and secreting factors that 
regulate inflammation and robust anti-microbial activity (Gunjan et al., 2018).  
 
Another group of Interferon stimulated genes, the IFN-induced dynamin-related 
GTPase families play a key role in these mechanisms. The proteins consists of the 47 
kDa immunity-related GTPases (IRGs), the 65 kDa guanylate-binding proteins (GBPs) 
and the 200–285 kDa very large inducible GTPases (VLIGs or GVINs) and the human 
transmembrane protein IRGM (see Fig. 5) (Kim et al., 2016). IRGs are not only pivotal 
in recruiting the various components of the autophagic machinery to bacterial 
phagosomes, but also have been implied in engaging in lysis of PCVs, releasing 
microbial components into the cytosol (Man et al., 2016). Although IRGs are 
expressed in mammals, this subset of GTPases is not present in primates. Thus, 
similarly to rodent IRGs, human IRGM facilitates trafficking of autophagic constituents 
to PCVs (Petkova et al., 2013). GBPs, as the single largest IFN-induced GTPase 
family remaining functional in primates, have emerged as a key factor in human cell 
autonomous immunity. Upon endocytosis of pathogens, GBPs are recruited to the 
PCV or to the membrane of cytosolic bacteria, where they engage in a so-far 
mechanistically uncharacterized membrane remodeling event, leading to the 
restriction of bacterial and protozoic growth within the cell (Tretina et al., 2019). 
Furthermore, GBPs are suggested to reduce virion infectivity and target replication 
complexes of ribonucleic acid viruses (Braun et al., 2019). Interestingly, GBPs are not 
only involved in pathogen killing, but also flexibly mediating inflammasome activation 
over various pathways, leading to the release of cytokines or inflammatory cell death 
(Kim et al., 2016). However, the exact mechanisms underlying GBP-mediated cell 






Figure 5 Phylogenetic tree of Interferon-inducible GTPases. Interferon(IFN)-inducible GTPases are clustered 
according to their genetic distance and the size of the triangle is proportional to the number of family members 
as well as the relative homology between them. KRAS (black) is the most distant relative of the IFN-inducible 
family. KRAS and the MX family (red) are induced by IFN-α/β, whereas all other families are induced by IFN-γ. 
Mx proteins are involved in viral and IRG and GBPs are involved in pathogen restriction. The IRG (green) and 




1.6.1 GBPs confer pathogen resistance and induce inflammasome activation 
 
GBPs are important members of the of host defense in vivo against bacterial and viral 
pathogens and parasites including T. gondii, L. monocytogenes, M. bovis, F. novicida, 
C. trachomatis, influenza virus and HIV (Degrandi et al., 2013; Haldar et al., 2013; Kim 
et al., 2011; Krapp et al., 2016; Meunier et al., 2015; Nordmann et al., 2012; Shenoy 
et al., 2012; Yamamoto et al., 2012). Several studies have shown a crucial role of GBP 
membrane recruitment and oligomerization for the antimicrobial function (Britzen-
Laurent et al., 2010; Shenoy et al., 2012). Consistently, GBPs have been 
demonstrated to homo- or hetero-oligomerize (Britzen-Laurent et al., 2010; Shenoy et 
al., 2012). During infection, GBPs target PCVs, such as the T. gondii PV (Degrandi et 
al., 2007; Degrandi et al., 2013; Kravets et al., 2012; Yamamoto et al., 2012), C. 
trachomatis inclusions (Haldar et al., 2013) and bacterial vacuoles of M. bovis (Kim et 
al., 2011) and S. typhimurium (Meunier et al., 2014). GBPs require isoprenylation for 
successfully targeting membranes (Modiano et al., 2005; Tietzel et al., 2009). They do 
not only restrict vacuolar pathogens, but they also target cytosolic pathogens, such as 
L. monocytogenes, F. novicida, HIV (Kim et al., 2011; Krapp et al., 2016; Meunier et 
al., 2015). Subsequent studies revealed that GBPs on mouse chromosome 3 (Gbpch3) 
play a role in the activation of the non-canonical inflammasome and caspase 11-
induced pyroptosis (Pilla et al., 2014). Another model describing the role of GBP in 
host defense implies that GBP targeting to PCVs and bacteria leads to rupture of PCVs 
and subsequent release of bacterial components into the cytosol. In addition, the 
exposure of pathogenic components results in indirect activation of inflammasomes 
since they act as ligands of pattern recognition receptors (see Fig. 6) (Man et al., 2015; 
Meunier et al., 2014). The duration of LPS stimulation may play a crucial role for GBP 
action. Thus, Pilla et. al. demonstrated that prolonged incubation with LPS shows  
reduced inflammasome activation (Pilla et al., 2014). Another study revealed that 
during C. muridarum infection, GBPs are required for inflammasome activation though 
GBPs fail to target the C. muridarum inclusions (Finethy et al., 2015). This implies that 
vacuolar or bacterial lysis is not the sole mechanism by which GBPs operate. 
19 
 
Figure 6 Schematic model of the function of GBPs and IRGs in response to infection in mice. 
The first panel shows the recruitment of GBPs and IRGs to the membrane of the pathogen‐containing 
vacuole (PCV) in immune and non‐immune cells infected with Toxoplasma gondii. GBPs and IRGs form 
higher order oligomer complexes on the PCV that leads to vacuolar disintegration and the escape of 
the toxoplasma into the cytoplasm. GBP2 further attacks and destroys the Toxoplasma membrane 
leading to pathogen killing. The second panels (middle) reveals how GBPs and IRGs attack the 
membrane of cytosolic bacteria such as Francisella novicida. Rupture of the pathogen membrane leads 
to release of bacterial DNA into the cytosol that is detected by the DNA‐sensing AIM2 inflammasome. 
GBPs are also recruited to the PCV surrounding vacuolar bacteria including Salmonella enterica 
serovar Typhimurium. Rupture of the vacuole leads to the release of lipopolysaccharides (LPS) that 
activates murine caspase‐11 and the non‐canonical NLRP3 inflammasome. The last panel (right) 
shows that Golgi-membrane bound GBP5 interferes with the infectivity of the RNA human 
immunodeficiency virus and simian immunodeficiency virus. GBPs and IRGs can be recruited to the 
replication complex induced by the RNA virus norovirus to compromise viral replication. GBP1 binds to 
actin monomers and disrupts actin filament formation which interferes with the delivery of the DNA virus 





1.6.2 GBPs are members of the dynamin superfamily 
 
GBPs belong to the family of dynamin related large GTP-binding proteins. GTPases 
of the dynamin superfamily share the property to hydrolyze nucleotides and form 
higher order helical oligomer assemblies on membrane tubules in vitro. The energy 
generated by GTP hydrolysis is translated into mechanical work often associated with 
membrane remodeling and thus, dynamin superfamily proteins are known as 
mechano-chemical enzymes (see Fig. 7) (Daumke and Praefcke, 2016; Faelber et al., 
2013). Dynamin superfamily GTPases have a low intrinsic affinity for nucleotides, 
which makes them catalytically independent from guanine nucleotide exchange 
factors. The relatively high GTPase activity of dynamin superfamily members 
increases with oligmerization (cooperativity) and stabilization of the oligomers on 
membrane platforms (Gao et al., 2010; Ghosh et al., 2006a; Praefcke et al., 2004a; 
Tuma and Collins, 1994; Warnock et al., 1996). Like other dynamin-related GTPases, 
GBPs show nucleotide-dependent oligomerization and fast cooperative GTPase 
activity (Ghosh et al., 2006b). However, unlike its peers membrane binding does not 
influence the GTP hydrolysis rate (Fres et al., 2010). Most recombinantly expressed 
dynamin superfamily members, such as Dynamin, Opa-1 and EHDs can form higher 
order oligomer assemblies on a membrane or protein filament template (Faelber et al., 
2019; Faelber et al., 2011; Stoeber et al., 2012). However, GBPs can only form distinct 
ring-shaped oligomers in the presence of nucleotide and when isoprenylated in vitro. 
These ring-shaped oligomers can further stack into rod shaped super structures and 
form completely independent of a stabilizing membrane tubule (Shydlovskyi et al., 
2017). Intensive phenotypical studies in vivo as well as the helical assembly and 
conformational changes upon GTP hydrolysis of dynamin on membrane tubules in 
vitro suggests a mechanism of membrane fission, while opposing movements in 
atlastin suggests that oligomerization tethers ER-tubules (Praefcke and McMahon, 
2004a). Recent evidence shows that recombinantly expressed GBP1 can tether giant 
unilamellar vesicles in vitro and induces hemi-fusion (Shydlovskyi et al., 2017). While 
GBPs share close homology to atlastin-1, the functional relevance of GBP-mediated 









1.7 Mechanisms of GTP hydrolysis of dynamin superfamily 
 
Proteins of the dynamin superfamily share a common architecture consisting of an N-
terminal large GTPase (LG-domain) domain responsible for nucleotide hydrolysis 
followed by one or more helical bundles that carry out the mechanical movement 
induced by it. Upon nucleotide binding, proteins of the dynamin superfamily dimerize, 
which stimulates GTP hydrolysis. The catalytic LG-domain contain 5 motifs that are 
required for nucleotide binding and hydrolysis (see Fig. 8) (Saraste et al., 1990). The 
G1 motif describes the P-loop with consensus sequence GxxxxGKS/T, where the 
serine/threonine residue coordinates the Mg2+-ion essential for GTP hydrolysis. 
Another important role of the P-loop is the stabilization of the transition state of GTP 
hydrolysis. In the case of dynamin, S41 coordinates a catalytic cation, whereas in 
GBP1 and atlastin-1, the side chain of R48 rotates into the nucleotide binding pocket 
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to stabilize the negative charge induced by the transition state (Bian et al., 2011; 
Byrnes and Sondermann, 2011a; Praefcke et al., 1999a). The G2 and G3 (also known 
as switch I and switch II) motif also stabilize the Mg2+-ion and interact with the γ-
phosphate of the nucleotide directly and undergo nucleotide dependent 
conformational changes. In dynamin, the G4 motif mediates specific binding to the 
guanine base in trans via D211 of the opposing monomer (Chappie et al., 2010). In 
EHDs, the G4 motif is followed by a methionine residue that sterically inhibits the 
binding of the guanine base, thus EHDs bind ATP instead (Daumke et al., 2007). 
Lastly, the G5 motif is not well conserved among the dynamin superfamily but may 




Figure 8  Nucleotide binding and hydrolysis of dynamin superfamily proteins. Sequence 
alignment of dynamin superfamily proteins in the G1-G4 motifs. Conserved canonical residues are 
highlighted in blue, other conserved residues in light grey. The catalytic arginine and serine in the P-
loop are shown in red. 
 
 
1.7.1 GTP hydrolysis in GBPs 
 
The LG domain of GBPs also contains the 4 main GTP binding motifs (G1-G4) but 
shows specific deviations from the consensus motifs that are largely shared with 
atlastin-1. In addition, GBPs have a distinct biochemical property amongst dynamin 
GTPases, i.e. they hydrolyze GTP to GMP in two consecutive cleavage reactions 
(Schwemmle and Staeheli, 1994). The crystal structure of full-length hGBP1 has been 
solved in the nucleotide-free state and in complex with the non-hydrolysable GTP 
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analogue GMPPNP (Prakash et al., 2000). The structures show that GBP1 has a 36-
kDa N-terminal large G (LG) domain and a 32-kDa carboxy-terminal α-helical 
elongated domain (Fig. 9a). Crystal structures of the N-terminal G domain of human 
GBP1 trapped at intermediate steps of GTP and GDP hydrolysis uncovered the 
molecular basis for nucleotide-dependent dimerization and cleavage of GTP (Ghosh 
et al., 2006b). These structures reveal that homo-dimerization occurs in a parallel 
head-to-head fashion and is regulated by structural changes in the switch regions 
leading to activation of GTPase activity (Fig. 9b). Structural information also shed light 
on the unique two-step cleavage mechanism of GTP by GBP1. Upon GTP cleavage, 
conformational changes in the LG-domain push the ribose backbone of the nucleotide 
forward inside the binding pocket to position the β-phosphate in the same position 
previously occupied by the γ-phosphate and thus enabling the consecutive cleavage 
with the exact same mechanism. R48 in the phosphate binding loop has been shown 
to have a crucial catalytic role in the GTPase reaction; a dimerization-dependent flip 
of its side chain into the nucleotide-binding pocket has been observed stabilizing the 
transition state of GTP hydrolysis (Fig. 9c). In addition, a catalytic serine stabilizes a 






Figure 9 Dimerization induced conformational changes of hGBP1 (a) hGBP1 full length crystal 
structure. hGBP1 consists of an N-terminal LG domain (red) and a C-terminal α-helical elongated 
domain (purple, cyan). The C-terminal helix α6 (cyan) interacts with the LG domain (red). Flexible loops 
are displayed in green. (b) Superimposition of hGBP1 LG domain (cyan) and hGBP1 full length in 
yellow. Upon dimerization. helix α3LG moves towards the C-terminal helices α6 and α6’. (c) Phosphate 
binding-loop of the structure of hGBP1 LG domain bound to GDP•AIF3 (red) superimposed on the P-
Loop of the GMPPNP-bound full length hGBP1 crystal structure (cyan). The major flip of Arg48 towards 
α-phosphate group of GBP • AIF3 is indicated by an arrow.  
 
 
In GBP1, K51, S52 as well as R48 are essential for GTP hydrolysis. However, GBP1 
mutants K51A and S52N cannot bind and hydrolyze GTP and do not dimerize, 
whereas mutant R48A can bind GTP, dimerizes but cannot hydrolyze the nucleotide. 
The switch I region of GBP1 does not only contribute in stabilizing the Mg2+-ion and 
transition state of hydrolysis, but also interacts with another large loop that binds the 
opposing molecule in trans. Residues H74 and K76 of the Switch I region have been 
proposed to specifically inhibit the second cleavage step of GTP hydrolysis (Praefcke 
et al., 2004b). GBP1 mutants H74A and K76A retain cooperativity but exhibit a 4-5 
fold reduced GTPase activity and no GMP production. The neighboring residues T75 
and S73 undergo major rearrangements during GTP hydrolysis and stabilize a 
catalytic water molecule (Praefcke et al., 2004a). Of note, GBP5 cannot hydrolyze 
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GTP to GMP but only to GDP (Neun et al., 1996b). Residues of the P-loop, switch I 
and switch II region are highly conserved amongst GBPs as well as residues H74 and 
K76 (Praefcke et al., 2004a). This difference in hydrolysis mechanisms implies that 
residues outside the conserved motifs play an important role in preference of one-step 
versus two-step GTP cleavage. GBPs bind GMP, GDP and GTP with similar affinity 
and hydrolyze GTP to GMP by two successive cleavages of two phospho-anhydride 
bonds (Ghosh et al., 2006a; Praefcke et al., 1999b). Subsequent studies indicated that 
the helical domain undergoes large-scale conformational rearrangements upon 
GTPase domain dimerization and membrane binding (Vöpel et al., 2014), as expected 
for a dynamin superfamily protein. While biophysical and biochemical studies suggest 
that the energy generated by the second cleavage step could be utilized in formation 
of polymers (Shydlovskyi et al., 2017), the physiological role of this process has thus 




1.8 Chlamydia trachomatis 
 
The Chlamydiaceae family of the chlamydiae phylum comprises 11 species that are 
pathogenic to humans or animals. Some species that are pathogenic to animals, such 
as the avian pathogen Chlamydia psittaci, or the fetal species Chlamydia abortus, can 
be transmitted to humans (Bachmann et al., 2014; Pospischil et al., 2002). Chlamydia 
trachomatis and Chlamydia pneumoniae are the major species that infect humans and 
contribute to a variety of diseases (see Fig. 10) (Malhotra et al., 2013). Chlamydia 
trachomatis (C. trachomatis) is the world’s leading cause of bacterial sexually 
transmitted infection. According to the world health organization, about 131 million new 
cases occur annually, where infection is most prevalent among sexually active young 
women and men (14-25 years) (WHO, 2018). C. trachomatis infects squamocolumnar 
cells which are located between the single layered cervical canal and multiple layered 
ectocervix in women or penile epithelial cells in men (Anttila et al., 2001; Cates and 
Wasserheit, 1991). Different chlamydia strains or serotypes are also known to infect 
genital, ocular or respiratory tissues. Chronic infection may lead to ectopic 
pregnancies, infertility and pelvic pain as well as pelvic inflammatory disease (PID) in 
women (Pavletic et al., 1999). C. trachomatis infections can be easily treated with 
antibiotics, however infection often remains undetected due to its  asymptomatic 
progress, which earned C. trachomatis the term “stealth pathogen” (Hafner, 2015; 
Redgrove and McLaughlin, 2014).  
C. trachomatis is an obligate intracellular gram-negative bacterium; thus it depends on 
host metabolites and protein machineries in order to survive (Bachmann et al., 2014). 
C. trachomatis can currently be classified in 19 different serovars that were historically 
established based on antigenic variation in the major outer membrane protein (MOMP) 
encoded by OmpA (Wang et al., 1985). Serovars A-C are common cause of trachoma, 
while serovars D-K cause urogenital infections. Serovars L1-L3 are associated with 





Figure 10 Phylogenetic tree of Chlamydia species and serovars. The Chlamydia genus is divided into the 
species C. pneumoniae, C. psittaci and C. trachomatis. C. trachomatis is divided in various serovars. Diseases 
caused by different species and serovars are displayed underneath. 
 
 
1.8.1 Chlamydia life cycle 
 
C. trachomatis is an intracellular pathogen with a unique biphasic life cycle (see Fig. 
11) (Hackstadt et al., 1997). Upon docking to the host cell via the formation of a 
trimolecular bridge of bacterial adhesin, host receptors and host heperan sulfate 
proteoglycans, infectious elementary bodies (EB) activate a host cell signaling 
cascade that allows entry of the pathogen into the host cytoplasm (Elwell et al., 2016; 
Rosmarin et al., 2012). Pre-synthesized type III secretion system effectors are injected 
into the host cell, where a subset of these effectors activate cytoskeletal 
rearrangements and facilitate host endocytosis. Internalized EBs rapidly differentiate 
into a second growth and replication phase called reticulate bodies (RB), initiated by 
the synthesis of bacterial proteins. RBs reside within a host membrane-derived 
pathogen containing vacuole termed inclusion that is actively uncoupled from the host 
endolysosomal pathway. During this growth phase, C. trachomatis expresses 
inclusion membrane proteins (Inc) that vastly exploit the retromer complex for nutrient 
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acquisition (Hackstadt et al., 1999). Furthermore, C. trachomatis acquires 
sphingomyelin and cholesterol from the Golgi apparatus, which is fragmented into 
Golgi mini-stacks that surround the inclusion in order to facilitate lipid delivery (Heuer 
et al., 2009). The Chlamydia inclusion is transported via microtubules to the 
microtubule organizing center (MTOC) (Clausen et al., 1997; Mital and Hackstadt, 
2011). RBs start to divide exponentially and the inclusion secrets other effectors that 
modulate many host cell pathways involved in cell cycle progression, metabolism and 
cell death (Omsland et al., 2014; Sun et al., 2016). The last stage of the life cycle 
embodies the secretion of EB effector proteins followed by differentiation into EBs. 
Infectious EBs can now be released from the host cell via lysis or extrusion and start 





Figure 11 Chlamydia trachomatis (C. trachomatis) life cycle. (C. trachomatis) is an obligate 
intracellular pathogen that resides within a specialized PCV and has a biphasic developmental cycle. 
Epithelial cells of the cervix are invaded by an infectious, but metabolically inactive, elementary body 
(EB). Upon endocytosis, the EB is engulfed by a membrane of the endosomal trafficking pathway, which 
allows it to replicate undetected within the cell. Within the inclusion, the EB grows into a larger 
metabolically active reticulate body (RB), which divides by binary fission. The RBs transform back into 
infective EBs within 2 days, which are released from the infected cell to infect neighboring cells. Figure 





1.8.2 Modulation of the innate immune response by Chlamydia 
 
Like other intracellular pathogens, chlamydia infection is detected by PRRs, which 
leads to cell-autonomous immunity and pro-inflammatory cytokine release (Bastidas 
et al., 2013). Multiple bacterial patterns such as LPS or peptidoglycans are recognized 
by TLR4 and TLR2 and subsequently activate the MYD88 dependent TRAF6-NFkB 
signaling axis that lead to the activation of the innate immune response (Shimada et 
al., 2012a). The bacterial second messenger cGAMP or cycling di-AMP can activate 
the cytosolic sensor synthase stimulator of interferon genes (STING) leading to the 
expression of ISG (Zhang et al., 2014). ISGs such as GBPs and IRG recognize and 
localize to chlamydia inclusions and promote bacterial clearance (Al-Zeer et al., 2013). 
Chlamydia infection leads to NLRP3 inflammasome activation that requires the 
generation of ROS and K+ efflux (Abdul-Sater et al., 2010). Chlamydial virulence 
factors can prevent or impair the innate immune response. A C. pneumoniae protease 
can cleave TRAF3 preventing phosphorylation and activation of interferon regulatory 
factor 3 (IRF3) augmenting ISG expression (Wolf and Fields, 2013). The C. 
trachomatis deubiquitinase dub1 can remove ubiquitination of IκBα, which leads to the 
stabilization of the inhibitory p65-p50-IkB complex and prevents nuclear translocation 
of NF-κB (Wolf et al., 2009). C. pneumoniae also prevents nitric oxide induction by 
downregulating the expression of inducible nitric oxide synthase (iNOS) (Abu-Lubad 
et al., 2014), while C. trachomatis downregulates the expression of interferon- induced 
protein with tetratricopeptide repeats 1 (IFIT1) and IFIT2 through the T3SS effector 
TepP (Chen et al., 2014). Other proteins such as CP0236 retain activating factors at 





2. Objective of this study 
 
Human guanylate binding protein 1 (hGBP1) belongs to the dynamin superfamily of 
GTPases and is involved in cell-autonomous defense against intracellular bacteria and 
parasites. During infection, hGBP1 is recruited to cytosolic pathogens, such as 
Shigella flexneri and pathogen-containing vacuoles, such as Chlamydia trachomatis 
inclusions, restricts pathogenic growth, and induces the activation of the 
inflammasome pathway and inflammatory cell death (pyroptosis). Amongst dynamin 
GTPases, hGBP1 has the unique catalytic activity to hydrolyze GTP to GMP in two 
consecutive cleavage steps. However, the functional significance of this activity in 
pathogenic restriction and inflammasome activation has remained elusive. In order to 
address this question, a structure-guided mutant that specifically abrogates GMP 
production, while maintaining fast cooperative GTP hydrolysis, was generated. The 
physiological function of this mutant was tested via complementation experiments in 
the monocyte precursor cell line THP-1 infected with the obligate intracellular 


















Chemicals used in this thesis are listed in the Appendix C. 
 
3.1.4 Enzymes  
 
















Constructs used in this thesis are listed in Appendix H. 
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3.1.9 S1 bacterial strains 
 
Table 1 S1 bacterial strains  
Bacterial strain Application 
E.coli Dh5α Molecular cloning 
E.coli BL21 DE3 Protein expression 
E.coli Top10 Lentivirus vectors molecular cloning 




pGEX-6P-1 (AmpR, GE Healthcare); pSKB2-LNB (KanR, based on pET28, Merck, 
Darmstadt, DE; Multiple cloning site exchanged against that of pGEX-6P-1, 
PreScission Protease cleavage site, O. Daumke, MDC-Berlin); pET-Duet-1 (KanR, 
Novagen); pLenti-CRISPR-V2 (AmpR, PuroR, CMV promotor, based on 3rd generation 
lentivirus vector); pLenti CMV GFP hygro (AmpR, HygroR, CMV promotor, based on 
3rd generation lentivirus vector that expresses eGFP, genes are cloned into BamHI, 
SalI to replace eGFP gene expression), psPAX2 (AmpR, 2nd generation lentiviral 
packaging vector), pVSVG (AmpR, 2nd generation lentiviral envelope vector). 
 
3.1.11 Media and Buffers 
 
Buffers used in this thesis and their compositions are listed in the Appendix F. Media 
are listed in Appendix G. 
 
3.1.12 Experimental model and subject details 
 
3.1.12.1 Cell Lines 
 
THP-1 cell lines (American Type Culture Collection TIB-202) were cultured in RPMI 
1640 with 10% fetal bovine serum (FBS). hGBP1 knock-out cell lines were generated 
by transfection of lentiCRISPRv2 containing hGBP1 single guide RNA sequences and 
single cell dilution. hGBP1 WT and mutant cell lines were generated by infection with 
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lentiviruses generated in HEK293T cell line (ATCC CRL-11268) expressing hGBP1 
proteins.  
 
3.1.12.2 Human Primary Macrophages 
 
Human primary macrophages were isolated from peripheral blood mononuclear cells 
(PBMCs) from healthy female donors, aged 20-40 years according to protocol number 
EA1/203/16 as approved by the ethics commission of Charité, Berlin. Human primary 
macrophages were cultured by adherence from PBMCs in RPMI 1640 with 10% FBS 
and 50 ng/ml human macrophage colony-stimulating factor (M-CSF) for 6 d. 
 
3.1.12.3 Microbe strain and culture 
 
C. trachomatis serovar L2 (ATCC VR-902B) was routinely, cultured, prepared, and 
propagated in HeLa cells (American Type Culture Collection CCL-2.1) as previously 




3.2.1 Molecular Biology 
 
3.2.1.1 Polymerase Chain reaction (PCR) 
 
DNA fragments were amplified with KOD Hot Start polymerase (Merck Millipore, DE) 
according to manufacturer’s instructions. 
 
3.2.1.2 Restriction digest 
 
DNA was digested with restriction endonucleases (Type II) from New England Biolabs 
(NEB) according to the manufacturer’s procedures. 
 
3.2.1.3 Agarose gel electrophoresis 
 




3.2.1.4 DNA purification 
 
Excised DNA bands were purified using the QIAquick Gel Extraction Kit (Qiagen) 




Concentration of plasmids and inserts was determined using the absorption at 259 
nm. 10 ng and a six-fold molar excess of insert were ligated using T4 DNA Ligase from 
NEB according to the manufacturer’s protocol. 
 
3.2.1.6 Preparation of chemically competent E. coli cells 
 
Chemically competent E. coli bacteria were prepared according to (Chung et al., 
1989). 
 
3.2.1.7 Transformation of chemically competent E. coli cells 
 
Plasmids were transformed using the heat shock method according to standard 
protocols. E. coli DH5α was used for plasmid propagation and E. coli BL21 (DE3) 
strain for protein expression. (Chung et al., 1989) 
 
3.2.1.8 Storage of E. coli cells 
 
For long-term storage of bacteria, 1 mL of a 5 mL LB overnight bacterial culture was 
mixed with 0.5 mL sterile glycerol and stored at -80 °C. 
 
3.2.1.9 Site-directed mutagenesis 
 
Site-directed mutagenesis was carried out by QuickChange mutagenesis (Stratagene) 
according to the manufacturer’s protocol. 
 




The hGBP1 mutants, R48A, K76A and G68A, were generated using the plasmid 
pQE80L-hGBP1 (a kind gift from Gerrit Praefcke) and the QuikChange site-directed 
mutagenesis kit (Stratagene, USA). The PCR product was cloned into a modified 
pET28 vector (pSKB-LNB2) and the mutation was verified by DNA sequencing. An 




3.2.2.1 Protein preparation 
 
WT and mutant hGBP1 variants with an N-terminal His6 tag were expressed using 
pSKB-LNB2 in E. coli strain BL21(DE3). The cells were grown at 37 °C in TB medium, 
and protein expression was induced at an optical density of 0.6-0.8 by the addition of 
50 µM isopropyl-β-d-thiogalactopyranoside (IPTG), followed by overnight incubation 
at 18 °C. Upon centrifugation, the cells were suspended in 50 mM Tris–HCl (pH 8.0), 
5 mM MgCl2, 300 mM NaCl, 5 mM β-mercaptoethanol, 10% (v/v) glycerol, 20 mM 
imidazole, 100 µM phenylmethylsulfonyl fluoride (PMSF) (Roth, Germany) and 1 µM 
DNase I (Roche) and mechanically lysed in a microfluidizer (Microfluidics). Following 
centrifugation (30,000 × g, 1 h, 4 °C), the protein in the cleared lysate was applied to 
a NiNTA column (GE Healthcare) and eluted with 20 mM Tris–HCl (pH 8.0), 5 mM 
MgCl2, 100 mM NaCl, 5 mM β-mercaptoethanol, 10% glycerol and 20 mM imidazole 
using a 20 mM to 500 mM imidazole gradient. It was followed by gel filtration via 
Superdex 200 (GE healthcare) in 50 mM HEPES pH 7.5,150 mM NaCl, 5 mM MgCl2 
and 2 mM dithiothreitol. Fractions containing monomeric hGBP1 were pooled and 
concentrated using Amicon filters with a 10 kDa cut-off to 10 mg/ml, shock-frozen in 
liquid nitrogen and stored at -80 °C. The concentration of hGBP1 was determined by 
ultraviolet spectrophotometry at 276 nm with the calculated molar absorption 
coefficient of 45,450 M-1 cm-1. 
 
3.2.2.2 Protein purification of farnesylated hGBP1  
 
Farnesylated hGBP1 was purified according to (Fres et al., 2010). The plasmid pGEX-
6P-I-hGBP1 was transformed into competent BL21 (DE3) E. coli cells (Novagen) 
containing the pRSF-FTase α/β construct for coexpression. Cultures were 
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supplemented with carbenicillin (50 µg/ml) and kanamycin (50 µg/ml) induced with 100 
µM isopropyl β-D-thiogalactopyranoside at an OD600 of 0.6–0.8. Cells were cultured 
for 16 h at 20°C, collected by centrifugation at 6,000 g for 20 min, and resuspended in 
50 mM Tris/HCl, pH 8.0, 300 mM NaCl, 5 mM MgCl2, 20 mM imidazole, 10 mM β-
mercaptoethanol. The cells were disrupted by multiple passage in a microfluidizer 
(Microfluidics). Unbroken cells and large debris were removed by centrifugation at 
60,000 g for 60 min at 4°C. The His-tagged hGBP1 was further purified using Nickel-
Sepharose 6 Fast Flow (GE Healthcare) and eluted with an imidazole gradient to 1,000 
mM in 130 mM KCl. Farnesylated and unmodified proteins were separated by Butyl 
Sepharose High Performance or Butyl Sepharose 4B Fast Flow (GE Healthcare) using 
a decreasing salt gradient from 1.5 M (NH4)2SO4 to 0 mM in 50 mM Tris/HCl, pH 8.0, 
2 mM MgCl2, 2 mM DTT. The removal of salt was carried out by gel filtration on 
Superdex 200 (GE Healthcare). 
 
3.2.2.3 GTP hydrolysis assay 
 
Non-farnesylated hGBP1 WT and mutants at the indicated concentrations were 
incubated with 1 mM GTP at 37 °C in buffer A (20 mM HEPES pH 7.5, 150 mM NaCl, 
2 mM MgCl2). Aliquots of the reaction were taken at the given time points, diluted in 
excess buffer A and flash-frozen in liquid nitrogen. Nucleotides were separated via 
reversed-phase chromatography (C-18, Hypersil) and their ratios quantified by 
integration of the 260 nm absorbance. 
 
3.2.2.4 Liposome preparation 
 
Liposomes were prepared by mixing 50 µl of Folch liposomes (total bovine brain lipids 
fraction I from Sigma (25 mg/ml) to 200 µl of a Chloroform/Methanol (1:0.3 v/v) mixture 
and dried under Argon stream. The liposomes were resuspended in Liposome Buffer 
and sonicated in water bath for 30 sec.  
 
3.2.2.5 Liposome co-sedimentation assays 
 
Liposomes (1 mg/ml) were incubated at room temperature with 10 µM of the indicated 
fhGBP1 construct in the presence of 1 mM GTP or 200 µM GDP, 300 µM AlF3 and 10 
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mM NaF or no nucleotide for 10 min in 50 µl reaction volume, followed by 213,000 g 
spin for 10 min at 20 C. The final reaction buffer contained 25 mM HEPES/NaOH (pH 
7.5), 150 mM NaCl and 1 mM MgCl2. The supernatant and pellet were analyzed via 
SDS-PAGE. 
 
3.2.2.6 Electron microscopy 
 
10 µM fhGBP1 WT was incubated in the presence of 1 mM GTP and the reaction 
subsequently diluted at 1:10 and spotted for 5 min at room temperature on carbon-
coated copper grids and negatively stained with 2% uranyl acetate. 10 µM fhGBP1 
G68A was incubated in the presence of 200 µM GDP, 300 µM AlF3 and 10 mM NaF 
for 15 min at room temperature, diluted at 1:10 and spotted on carbon-coated copper 
grids and negatively stained with 2% uranyl acetate. Electron grids were imaged with 
a transmission electron microscope at 80 kV and acquisition was done with a CCD 
camera. 
 
3.2.2.7 Structural analysis and sequence alignment 
 
Crystal structures were analyzed with PyMOL (Molecular Graphics System Version 
1.8. Schroedinger, LLC) and Chimera (Pettersen et al., 2004) The molecular 
superposition was created in Chimera. Sequence alignments were performed with 
MUSCLE (Madeira et al., 2019) and figures prepared with Chimera. 
 
3.2.3 Cell and infection biology 
 
3.2.3.1 Cell culture treatments and C. trachomatis infection 
 
Human primary monocyte–derived macrophages (hMDMs) were prepared by 
adherence from whole-blood fractions of healthy donors. Primary monocytes were 
cultured in RPMI 1640 with 10% FBS and treated with 50 ng/ml M-CSF for 6 d. THP-
1 cells were cultured in RPMI with 10% FCS.  
 
When indicated, THP-1 cells were differentiated with 100 nM phorbol 12-myristate 13-
acetate (PMA) for 24 h. C. trachomatis bacteria were cultured as previously described 
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(Al-Zeer et al., 2013) and infected at MOI 5 for inclusion count and infectivity assay, 
or at MOI 30 for inflammasome activation. For allopurinol specificity and 
inflammasome control experiments, THP-1 cells or hMDM were transfected either with 
1 µg Flagellin (i.e., NLRC4 inflammasome stimulation) or 1 µg poly(dA:dT) (i.e., AIM2 
inflammasome stimulation) for 6 h using Profect P1 reagent (Targeting Systems) or 
Lipofectamine RNAimax (Invitrogen), respectively. THP-1 cells or hMDMs were 
primed for 16 h with 100 nM LPS or 100 nM LPS + 100 nM IFN-γ, respectively, and 
treated with 5 mM ATP (NLRP3) for 4 h or transfected with 1 µg LPS (CAS4) for 6 h 
using FuGENE HD transfection reagent (Promega). For NLRP3 inhibition 
experiments, THP-1 cells or hMDMs were treated with 300 nM MCC950 for 1 h prior 
to 24 h infection with C. trachomatis. For cell death pathway determination, THP-1 
hGBP1 R48A mutant cells were treated with 12 µM IM-54, 1 µM Bafilomycin-A1, 40 
µM necrostatin-1, 5 µM ferrostatin-1 or 15 µg/ml Ac-YVAD-CMK 1 h prior to 24 h 
infection with C. trachomatis. For the metabolite feedback experiments, THP-1 hGBP1 
KO cells and THP-1 hGBP1 G68A mutant cells were treated with 0.5 mM or 1 mM 
guanine or guanosine for 1 h post infection (p.i.) with C. trachomatis. 
 
3.2.3.2 siRNA transfection 
 
THP-1 cells were seeded in a 12 well plate in 1 ml Opti-MEM at a density of 5x105 /ml. 
Per well transfection, 246.5 µl of Opti-MEM + 3.75 µl of 20 µM siRNA were mixed with 
246.5 µl of Opti-MEM with 3.75 µl siRNAmax transfection reagent from Invitrogen and 
incubated for 10 min at RT. 500 µl of transfection mix were transfected per well of 
THP-1 by drop by drop release. 6 hrs post transfection, the Opti-MEM was replaced 
by 2 ml RPMI + IFN-γ at 50 ng/ml and LPS at 100 ng/ml. Cells were further infected 
with C. trachomatis or harvested 48 hrs post transfection. 
 
3.2.3.3 CRISPR/Cas9-mediated knockout of hGBP1 and complementation in THP-1 
 
hGBP1 single guide RNA sequences from Feng Zhang´s Gecko database were cloned 
into lentiCRISPR v2 and transfected into THP-1 cells with Fugene HD transfection 
reagent (Promega). Two days after transfection, the cells were diluted into single 
clones and seeded into 96 well plates. Successful knockout of hGBP1 was confirmed 




hGBP1 knockout cells were complemented with lentiviral constructs that express 
GBP1 WT, R48A, K76A or G68A. The genes exhibit two silent mutations on the sgRNA 
sequence to disable targeting by Cas9. Lentiviruses were generated in HEK293T cells 
by transfection with a lentivirus vector containing GFP (as empty vector control), 
FLAG-hGBP1 WT, FLAG-hGBP1 G68A, FLAG-hGBP1 R48A and its packaging 
vectors PsPax2 and VSVG. The vector contains a hygromycin resistance gene. 6 
hours after transfection the media was replaced with fresh DMEM and 48-56 h post 
transfection the media was filtered with a 0.4 µm filter and applied to 1.0.x 107 THP-1 
cells. 24 h post infection with virus, the media was changed to fresh RPMI + 10% FCS 
media. After 3 days, THP-1 cells positive for GBP1 expression were selected via 
hygromycin at increasing concentrations from 100-400 µg/ml over 2 weeks. GBP1 
expression was tested via immunoblotting against FLAG and endogenous GBP1. 
  
3.2.3.4 Immunostaining and ASC speck count 
 
THP-1 cells were differentiated for 24 h with 100 nM PMA and infected with C. 
trachomatis at MOI 5 or 30 for 24 h. Cells were fixed in 4% Paraformaldehyde (PFA) 
or 2% PFA for a specific UA staining. After fixation, the cells were permeabilized with 
0.3% Triton-X100 for 10 min and blocked in 3% bovine serum albumin (BSA) in 
phosphate-buffered saline or 10% horse serum, 100 mM glycine for 1 h at room 
temperature. The cells were stained for C. trachomatis inclusions (goat anti-MOMP 
1:150), ASC (rabbit anti-ASC 1:300, Proteintech), Xanthine Oxidase (mouse anti XO, 
1:50 Santa Cruz biotechnology), hGBP1 (rat anti hGBP1 1:50, Santa Cruz 
biotechnology), rabbit anti uric acid (UA, 1:1500), at 4 °C, overnight. ASC specks were 
counted by evaluating 500 cells per experiment. 
 
3.2.3.5 Inclusion count 
 
THP-1 cells were differentiated with 100 nM PMA for 24 h and stimulated with 100 nM 
IFN-γ, 100 nM LPS for 24 h. The cells were infected with C. trachomatis at MOI 5. 
After 1 h of infection, the media was changed to fresh RPMI, and the cells incubated 
for another 23 h. The cells were fixed 24 h post infection (p.i.) with 4% PFA and stained 
for C. trachomatis and 4′,6-diamidino-2-phenylindole (DAPI). The number of inclusions 
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per nuclei was determined following three independent experiments. In each 
experiment, 500 cells were evaluated. Significance was determined by one-way 
ANOVA. 
 
3.2.3.6 Infectivity assay 
 
Host cells were seeded in 6-well plates, treated as above, infected with C. trachomatis 
diluted in infectious medium at MOI 5 and incubated at 35 °C and 5% CO2. Two hours 
p.i., the cells were washed and loaded with fresh medium containing 100 U/ml IFN-γ. 
Control infected cells were not treated with the cytokine. The cell cultures were then 
incubated as above for 48 h. The formation of infectious C. trachomatis progeny in a 
secondary infection was assessed by infectivity titration assay (Al-Zeer et al., 2009). 
Briefly, the infected cells were mechanically destroyed using glass beads. Resulting 
lysates were serially diluted in infectious medium and then used to inoculate HeLa 
cells for 2 h. The cells were then washed and further incubated for 24 h in RPMI 
medium with 5% FBS and 1 µg/ml cycloheximide. One day later, the cells were fixed 
with 4% PFA and stained for C. trachomatis, as described above. Forty confocal 
images were taken per sample and experiment at 400x magnification, and the area of 
each image calculated and divided by the area of one well. The infectivity titer is 
expressed as the number of inclusions (IFU/ml) IFU/ml = no. inclusions in 10 fields/10 
× no. fields in a well × dilution factor. Significance was determined by a Student´s t-
test. 
 
3.2.3.7 LDH cytotoxicity assay 
 
THP-1 cells (1.7 x 105 per well) or hMDMs (2.0 x 105 per well) were stimulated with 
100 nM IFN-γ and 100 nM LPS for 16 h and infected with C. trachomatis at MOI 30 for 
24h in a 96-well plate or 24-well plate (hMDMs). LDH release upon infection was 
measured using CytoTox-ONE™ Homogeneous Membrane Integrity Assay kit 
(Promega, according to manufacturer´s instructions). LDH release was calculated by 
subtraction of cell culture background and normalization to average maximum 






THP-1 cells (1.7 x 105 per well) or hMDMs (2.0 x 105 per well) were stimulated with 
100 nM IFN-γ and 100 nM LPS for 16 h and infected with C. trachomatis at MOI 30 for 
24 h in a 96-well plate or 24-well plate (hMDMs). IL-1β measurements were conducted 
using the Human IL-1 beta/IL-1F2 DuoSet ELISA kit according to the manufacturer´s 
instructions. Significance was determined by two-way ANOVA. 
 
3.2.3.9 mtROS measurement 
 
THP-1 cells (2 x 105 per well) were stimulated with 100 nM IFN-γ and 100 nM LPS for 
16 h and infected with C. trachomatis at MOI 30 for 24 h in a 96-well plate. 
Mitochondrial ROS were measured by reaction with MitoSOX™ Red dye in a 
microplate reader according to manufacturer´s instructions (fluorescence Ex.: 400 nm/ 
Em.: 595 nm). Significance was determined by two-way ANOVA. 
 
3.2.3.10 Uric acid measurement 
 
THP-1 cells (2 x 105 per well) were stimulated with 100 nM IFN-γ and 100 nM LPS for 
16 h and infected with C. trachomatis at MOI 30 for 24 h in a 96-well plate. Uric acid 
concentration in cell culture supernatants was measured using Uric acid/Uricase 
Assay Kit from Cell Biolabs, inc. according to the manufacturer´s instructions. Briefly, 
uric acid reacts with water and oxygen in the presence of the enzyme uricase to 
produce allantoin and H2O2. In the presence of HRP, a fluorescence probe reacts with 
H2O2 in a 1:1 stoichiometry to produce a highly fluorescent product (Ex.: 535 nm/ Em.: 
595 nm), which can be measured using a microplate reader. 
 
3.2.4 Quantification and statistical analysis 
 
3.2.4.1 Image Analysis 
 
For inclusion and ASC speck counting, approximately 30-40 images were taken per 
experiments representing approximately 500 cells. Nuclei, C. trachomatis inclusions 
and ASC specks were manually counted from immunostaining and analyzed 
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statistically using one-way ANOVA in Graphpad Prism software. Infectivity titer was 
determined by counting C. trachomatis inclusions and nuclei from 40 images per 
sample and the area of each image calculated and divided by the area of one well. 
The infectivity titer is expressed as the number of inclusions (IFU/ml) IFU/ml = no. 
inclusions in 10 fields/10 × no. fields in a well × dilution factor. Significance was 
determined by Student´s t-test using Graphpad Prism software. 
 
3.2.4.2 Cell Biological Assays 
 
ELISA, LDH and mtROS assays were analyzed using two-way ANOVA and Uric acid 








4.1 The hGBP1 G68A mutant retains fast, cooperative GTP hydrolysis while displaying 
reduced GMP production. 
 
Since the two-step cleavage mechanism of GTP to GMP by hGBP1 requires the 
movement of the ribose backbone of the cleaved GDP moiety, a point mutation in the 
G-domain of hGBP1 was designed to sterically lock GDP in the nucleotide binding site 
and thus prevent the second hydrolysis step (Fig. 12). Several glycine residues 
surround GTP in the catalytic site and provide the necessary peptide backbone 
flexibility that enables nucleotide relocation. Amongst these glycines, Gly68 was 
chosen for two reasons. First, consistent with the reported crystal structure (Ghosh et 
al., 2006b), Gly68 is in close proximity to the ribose moiety of GDP during GTP 
hydrolysis, and its mutation into a bulkier amino acid might consequently interfere with 
nucleotide displacement. Second, when the sequence of hGBP1 is compared to that 
of hGBP5 that can cleave GTP only to GDP (Neun et al., 1996a; Wehner and 








Figure 12 Design of a structure- based GMP production mutant in the LG domain.  
(Top) Superimposition of hGBP1 G-domain structures bound to GDP·AlFx (brown, pdb 2b92) and 
GMP·AlFx (blue, pdb 2b8w). (Bottom) Sequence alignment of human GBP1, GBP2 and GBP5. Position 
68 is marked in red. 
hGBP1 55 MNKLAGKKKGFSLGSTVQSHTKGIWM 80
hGBP2 55 MNKLAGKKNGFSLGSTVKSHTKGIWM80










Thus, recombinant hGBP1 WT and G68A mutants were generated and purified (see 
section 3.2.2.1) The G68A mutant of hGBP1 retained a similar GTP hydrolysis rate to 
that of the wild-type (WT) protein (Fig. 13A). However, the G68A mutation completely 
abolished GMP production (Fig. 13B-13D). Mutations in K76 or H74 in the conserved 
switch I region of the G-domain have been previously shown to abrogate GMP 
production (Praefcke et al., 2004b). However, unlike G68A, the K76A mutation led to 
a general reduction in GTP hydrolysis (Fig. 13A). Mutating R48, which stabilizes the 
transition state of GTP hydrolysis, to alanine completely abolished GTP hydrolysis 




Figure 13 Linear rates of GTP hydrolysis, GDP and GMP production by hGBP1 WT and point 
mutants. GTP hydrolysis (A), GDP production (B) and GMP production (C) of 2 µM hGBP1 WT (), 
G68A (▪), K76A () or R48A () were followed by an HPLC-based approach. Data represent the 
average of two independent measurements ± range. Error bars smaller than the data points are not 
indicated. (D) End product formation of GTP hydrolysis after reacting with 2 µM of indicated hGBP1 
proteins for 30 minutes, n=3. Error bars indicate the standard error of the mean (SEM). *P<0.05, 



















































































To further compare the specific catalytic activities of the mutants, a detailed time- and 
concentration-dependent enzymatic characterization was performed. These results 
indicate that in comparison to the WT protein, I show that the dimerization- dependent 
GTP hydrolysis activity of the G68A mutant was not impaired. While the K76A mutation 
retained cooperativity, this mutation led to a 4-fold decrease in the maximal GTP 














Previous studies indicated that in vitro farnesylated hGBP1 can bind liposomes 
composed of bovine brain lipids (Folch liposomes) and form ring-like structures in the 
presence of transition state analog GDP AlFx, indicating that GTP hydrolysis is 
important for the mechano-chemical function of hGBP1 on membranes. Critically, in 
line with its generally reduced GTP hydrolysis activity, it has been shown that K76A 
mutant fails to bind liposomes and to form such high order oligomeric state 
(Shydlovskyi et al., 2017). In contrast, recombinantly expressed and farnesylated 
hGBP1 G68A bound to Folch liposomes (Fig. 15) and formed ring-like structures (Fig. 






















Figure 14 Dimerization-dependent GTP hydrolysis rate of hGBP1 WT and point mutants. 
Cooperative GTP hydrolysis rate of indicated hGBP1 proteins obtained by plotting specific activity 
against protein concentration. Data represent the average of two independent measurements ± range. 




Figure 15 Liposome co-sedimentation assay. Folch liposome co-sedimentation assay of fGBP1 WT 







Figure 16 Negative stain electron microscopy images of fhGBP1 WT and G68A. (Top) negative 
stain EM images of a reaction of 10 µM fhGBP1 WT in the presence of 1 mM GTP at 1:10 dilution. 
(Bottom) negative stain EM images of a reaction of 10 µM fhGBP1 G68A in the presence of 200 µM 
GDP, 300 µM AlF3 and 10 mM NaF at 1:10 dilution. 
 
 
Collectively, among the tested hGBP1 mutants that abolished GMP production, the 
G68A mutant hydrolyzed GTP most similar to WT. Therefore, this mutant was utilized 




4.2 Consecutive GTP hydrolysis is dispensable for the restriction of C. 
trachomatis. 
 
In order to characterize the role of the second-step GDP hydrolysis for pathogen 
restriction, hGBP1 was knocked out in THP-1 cells, a human monocyte cell line, using 
CRISPR-Cas9 technology (see section 3.2.3.3). Subsequently, the KO cells were 
reconstituted with lentivirus-expressed WT hGBP1, the hGBP1 mutants, R48A, K76A, 
G68A, or GFP as a negative control. The depletion of endogenous hGBP1 and 










Parental THP-1 cells and the newly generated cell lines were infected with C. 
trachomatis, followed by immunostaining against major outer membrane protein 
(MOMP), an antigen of C. trachomatis (see Fig. 18A) In agreement with a previous 
study, hGBP1 KO cells presented an increased number and size of C. trachomatis 
inclusions (Fig. 18A-18C) (Al-Zeer et al., 2013). Re-expression of WT hGBP1, but not 
the R48A mutant, reduced C. trachomatis inclusions, indicating that hGBP1-mediated 
GTP hydrolysis is vital for C. trachomatis restriction. The switch I mutant K76A showed 
impaired restriction of C. trachomatis although not to the same extent as the GTP 
hydrolysis-deficient hGBP1 mutants re-expressed in the KO cells (Fig. 19). This is 
consistent with the impaired GTP hydrolysis activity of K76A mutant, and K76A mutant 
was thus not further investigate in this study. Surprisingly, the G68A mutant restricted 

































Figure 17 Western blot of hGBP1 WT and point mutants in THP-1. CRISPR-Cas9-mediated 
knock-out of hGBP1 and stable overexpression of hydrolysis mutants as shown by immunoblotting 





Figure 18 hGBP1 G68A mutant is able to restrict C. trachomatis. (A) Representative images of 
indicated THP-1 cell lines stimulated with IFN-γ and infected with C. trachomatis at MOI 5 for 24 h. 
White arrows indicate inclusions. Red, C. trachomatis. Blue, DAPI. The scale bars are 20 µm. (B, C) C. 
trachomatis inclusions larger (B) or smaller (C) than the size of 2 µm diameter were quantified by 
































































Figure 19 Cell line THP-1 hGBP1 K76A does not restrict C. trachomatis growth. Western blot 
confirming re-expression of the hGBP1 K76A in THP-1 hGBP1 KO cells (left) and inclusion count (right) 
of THP-1 stimulated with IFN-γ and infected with C. trachomatis at MOI 5 for 24 h. C. trachomatis 
inclusions larger than the size of 2 µm diameter were quantified by normalization to the number of nuclei 
(30-40 per image). 
 
 
To further substantiate these findings, the requirement of consecutive GTP hydrolysis 
for restricting infectious C. trachomatis progeny was tested by conducting a re-
infection assay in HeLa cells. In this assay, C. trachomatis are isolated from infected 
THP-1 cells and re-infected to HeLa cells. This quantifies actual viability of the bacteria 
as opposed to simple inclusion counts, which could potentially include inactive or non-
infectious bacteria. While hGBP1 KO cells and R48A mutants increased the 
production of C. trachomatis elementary bodies, WT hGBP1-expressing cells and 
G68A mutants significantly reduced their production (Fig. 20A and 20B). Thus, 







Figure 20 hGBP1 G68A can restrict C. trachomatis infectious progeny (A) Influence of hGBP1 
mutants on C. trachomatis infectious progeny. C. trachomatis inclusions were isolated from the infected 
various THP-1 cells; the infectivity was determined by the re-infection of HeLa 229 cells, normalized to 
the parental THP-1 cells. Representative images of reinfection (B) Bar diagram of re-infection of HeLa 
229 from C. trachomatis infected THP-1 GBP1 cell lines. Red, C. trachomatis. Blue, DAPI. All error bars 
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4.3 Consecutive GTP hydrolysis is required for inflammasome activation 
 
It has previously been demonstrated that GBPs are required for inflammasome 
activation (Fisch et al., 2019; Man et al., 2015; Meunier et al., 2014; Meunier et al., 
2015; Pilla et al., 2014). Inflammasome activation leads to Gasdermin D-mediated cell 
death (pyroptosis), caspase-1-dependent processing, and the secretion of interleukin-
1β (IL-1β). Therefore, the inflammasome activation of C. trachomatis-infected THP-1 
cells was evaluated by measuring lactate dehydrogenase (LDH) release (a readout of 
cell death) and IL-1β secretion. As expected, KO cells showed a significant reduction 
in cell death rate as compared with the parental cells (Fig. 21A and 21B). These 
defects were rescued by re-expression of hGBP1 WT. In contrast, expression of the 




Figure 21 The consecutive hydrolysis of hGBP1 is required for cytokine release and pyroptosis. 
(A) Inflammasome activation was examined by IL-1β ELISA. Cell lines were infected with C. trachomatis 
at MOI 30 for 24 h, n=3; two-way ANOVA.(B) Cell death was measured by measuring release of lactate 
dehydrogenase in LPS + IFN-γ stimulated THP-1 cells infected with C. trachomatis at MOI 30 for 24 h, 
n=3; two-way ANOVA. 
 
 
Unexpectedly, R48A cells showed somewhat increased cell death despite the clear 
blockade of inflammasome activation (Fig. 21B). Screening of inhibitors that target 
various cell death mechanisms showed that R48A mutants died due to necroptosis 
(Fig. 22). Therefore, infected cells can engage in necroptotic cell death when 
hydrolysis activity of hGBP1 is compromised, but not when hGBP1 is completely 
absent. The surprising link between the hGBP1 R48A mutation and the induction of 




















































Interestingly, the G68A mutant failed to induce cell death and secrete IL-1β in an 
infection-dependent manner, which was comparable with KO cells (Fig. 21A and 21B). 
Also, the status of caspase-1 activation by Western blotting of cell culture supernatants 
was examined. In comparison to KO cells, G68A mutants reduced the secretion of 
mature caspase-1 subunit p20 (Fig. 23). These findings lead to the conclusion that the 
reduced secretion of caspase-1 and inflammatory cytokines are the results of impaired 
inflammasome activation.  
  
***
C. trachomatis - +
hGBP1 R48A
Figure 22 THP-1 hGBP1 R48A dies by necroptosis. LDH release of THP-1 hGBP1 R48A cell line 
stimulated with IFN-γ + LPS for 16 h, followed by infection with C. trachomatis at MOI 30 for 24 h. Cells 
were co-treated with indicated cell death inhibitors for 24 h, n=3; two-way ANOVA. Cell death inhibitors 
- IM54, necrostatin-1, ferrostatin-1, bafilomycin and Z-DEVD-FMK that inhibit necrosis, necroptosis, 











A previous study demonstrates that hGBP2 can also hydrolyze GTP to GMP but much 
less efficiently than hGBP1 (~10% of hGBP1) (Neun et al., 1996a). Depletion of 
hGBP2 in THP-1 cells led to a non-significant marginal reduction of IL-1β release and 
cell death (Fig. 24A), despite an efficient knock-down (Fig. 24B). Thus, activation of 
the inflammasome is not a general feature of all hGBPs. Instead, it may be related to 




































Figure 23 Western blot of caspase-1 precursor and processed p20 in infected THP-1 hGBP1 WT 
and mutant cell lines. Inflammasome activation was examined by immunoblotting against caspase-1. 





Figure 24 shRNA knockdown of hGBP2 in THP-1 cells shows hGBP2-independent 
inflammasome activation. (A) hGBP2 knock-down by shRNA in THP-1 cells. IL-1β ELISA and LDH 
release following infection with C. trachomatis at MOI 30 for 24 h, n=3; two-way ANOVA. (B) Stable-
knock down of hGBP2 in THP-1 cells shown by immunoblotting against hGBP2. Cells were treated with 










4.4 hGBP1 activates the NLRP3 inflammasome 
 
hGBPs have been shown to activate the canonical NOD-, LRR- and pyrin domain-
containing protein 3 (NLRP3) inflammasome either directly or indirectly through the 
non-canonical caspase-4-mediated pathway. hGBP5 has been proposed to be part of 
NLRP3 to stabilize inflammasome formation (Shenoy et al., 2012) and hGBP1 has 
been suggested to activate NLRP3 during C. trachomatis infection (Finethy et al., 
2015). Alternatively, hGBPs have been proposed to lyse bacterial membranes and 
release LPS and indirectly activate NLRP3 through the non-canonical inflammasome 
caspase-11/-4/5 (Meunier et al., 2014; Pilla et al., 2014). However, the exact 
mechanism of NLRP3 activation during C. trachomatis infection has been unclear. 
To first confirm whether consecutive GTP hydrolysis is required for NLRP3 
inflammasome activation, hGBP1 KO cells that re-express hGBP1 WT, the R48A or 
G68A mutant were infected with C. trachomatis and infection-dependent NLRP3 
activation was examined by monitoring the speck formation of the inflammasome 
adaptor ASC (Apoptosis-associated Speck-Like protein containing a CARD). In line 
with the previous experiments, G68A mutants formed fewer ASC specks as compared 






Figure 25 Differential ASC speck formation in C. trachomatis infected THP-1 hGBP1 cell lines. 
(A) Representative images of ASC specks stained in THP-1 hGBP1 cell lines infected with C. 
trachomatis. Red, ASC specks. Blue, DAPI. Scale bar, 10 µm. (B) Quantification of inflammasome ASC 
specks of indicated cell lines infected with C. trachomatis at MOI 30 for 24 h, n=3; one-way ANOVA. All 
error bars indicated SEM. *P<0.05, **P<0.01, ***P<0.001. 
In order to verify that NLRP3 is the major inflammasome pathway induced by C. 
trachomatis infection, the cells were treated with the NLPR3 inhibitor MCC950. 
MCC950 treatment largely abolished infection-induced IL-1β secretion and pyroptosis 
(Fig. 26A). The effect of MCC950 was also confirmed in a culture of human primary 
macrophages (Fig. 26B). 
 
 



















Figure 26 NLRP3 inhibitor MCC950 significantly reduces cytokine release and pyroptosis in 
THP-1 cells and primary human macrophages in response to C. trachomatis infection. (A) IL-1β 
ELISA and LDH release for THP-1 cells treated with MCC950 and infected with C. trachomatis at MOI 
30 for 24 h, n=3; two-way ANOVA. (B) IL-1β ELISA and LDH release for hMDMs treated with MCC 50 




In order to test whether caspase-4 cleavage and activation cause NLRP3 
inflammasome activation, caspase-4 was transiently knocked down in THP-1 cells. 
Transient knock down of caspase-4 inhibited IL-1β release and cell death in response 
to intracellular LPS, a well-established activator of caspase-4 (Fig. 27A) (Shi et al., 
2014). In contrast, caspase-4 knock down had no effect on IL-1β secretion and 
pyroptosis following C. trachomatis infection (Fig. 27A). The efficiency of caspase-
knockdown was confirmed by western blotting (Fig. 27B). Taken together, these 
results suggest that hGBP1-mediated consecutive hydrolysis of GTP to GMP is 
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Figure 27 hGBP1 activates the caspase-4-independent NLRP3 inflammasome pathway upon C. 
trachomatis infection. (A) IL-1β ELISA and LDH release for THP-1 and THP-1 caspase-4 knock down 
cells, transfected with LPS or infected with C. trachomatis at MOI 30 for 24 h, n=3; two-way ANOVA. 
(B) Transient knock down of caspase-4 in THP-1 cells was validated by immunoblotting against 
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4.5 Uric acid synthesis is required for inflammasome activation upon 
Chlamydia infection 
 
The potential mechanism by which hGBP1 promotes NLRP3 inflammasome activation 
was further investigated. Several intracellular danger patterns are known to activate 
the NLRP3 inflammasome, among which uric acid (UA) is one (Braga et al., 2017; 
Kimball et al., 2019; Martinon et al., 2006a). Interestingly, GMP can be catabolized to 
UA through three enzymatic steps (Fig. 28). This suggests that hGBP1 oligomerization 
on the vacuolar membrane results in a local rise in GMP concentration. Subsequently, 













An essential prediction of this model is that enzymes involved in the metabolism of 
GMP to UA would be localized to the PCV or regulated during infection. Indeed, as 
Chlamydia are obligate intracellular pathogens, many metabolites and metabolic 
enzymes are known to be hijacked from the host system and recruited to the inclusion 
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Figure 28 Metabolic pathway of GMP degradation to uric acid. The enzyme GDA was knocked 





key enzyme involved in the last step of xanthine oxidization to UA was examined. In 
uninfected cells, xanthine oxidase was evenly distributed throughout the cell. In 
contrast, this enzyme displayed a marked vesicular pattern in infected cells, which 
strongly co-localized with the inclusions (Fig. 29).  
 
 
Figure 29 XO colocalizes with C. trachomatis in infected THP-1 Representative images of xanthine 
oxidase (red) immunostaining with or without C. trachomatis (green) infection. The line tracing 
quantification of the white dashed line is shown at the bottom. Scale bar = 10 µm. 
 
Furthermore, in microarray data from a previous study, it was observed that the 
transcripts of guanine deaminase (GDA), which catalyzes the upstream step of 
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xanthine oxidase, are significantly increased upon C. trachomatis infection (Mehlitz et 







It was then investigated whether blocking UA synthesis can impair inflammasome 
activation in response to C. trachomatis infection. First, allopurinol, a clinically 
approved xanthine oxidase inhibitor used for gout medication, was employed. 
Remarkably, co-treatment of cells with allopurinol mitigated C. trachomatis-induced 
pyroptosis and ASC speck formation in a concentration-dependent manner (Fig. 31 
and 32A).  
  


















Figure 30 induction transcription of GDA upon C. trachomatis infection in THP-1 cells. mRNA 
levels of GDA in THP-1 cells upon infection with C. trachomatis or non-infected at MOI 30 for 24 h, 






Accordingly, a sharp reduction of IL-1β secretion in the cell supernatant was detected 
(Fig. 31), whereas IL-1β expression was not affected at the mRNA level (Fig. 32B).  
 
 
Figure 32 Dose-dependent reduction of ASC specks and IL-1β transcription level in THP-1 
infected with C. trachomatis (A) Quantification of inflammasome ASC specks in THP-1 cells upon 
infection with C. trachomatis at MOI 30. The cells were co-treated with increasing concentrations of 
allopurinol (100 µM and 500 µM) for 24 h, n=3,; one-way ANOVA. (B) mRNA levels of IL-1β in THP-1 















































































Figure 31 Allopurinol treatment of C. trachomatis infected THP-1. LDH release and IL-1β 
ELISA of THP-1 cells treated with increasing concentrations of allopurinol (50, 100 and 500 µM). 
The cells were stimulated with IFN-γ + LPS and infected with C. trachomatis at MOI 30 for 24 h, 
n=3; two-way ANOVA. 
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Allopurinol blocked inflammasome activation in human primary macrophages as well 
(Fig. 33B). Importantly, the effect of allopurinol was specific to C. trachomatis infection, 
because it had no effect on other inflammasome activators, such as poly (dA:dT), 




Figure 33 Inflammasome control experiments in THP-1 and hMDM. (A) IL-1β ELISA and LDH 
release of THP-1 cells, which were transfected with Flagellin, poly (dA:dT) or stimulated with LPS + 
ATP and co-treated with allopurinol (500 µM) as indicated, n=3; two-tailed Student´s t-test. (B) IL-1β 
ELISA and LDH release of THP-1 cells transfected with Flagellin, poly (dA:dT) or stimulated with LPS 
+ ATP or infected with C. trachomatis and co-treated with allopurinol (500 µM) as indicated, n=3; two-
tailed Student´s t-test. 
 
 
As a second approach, the metabolic pathway of UA production was genetically 
inactivated. To this end, the enzyme GDA was transiently knocked down due to its 
specific involvement in GMP catabolism rather than that of AMP. The efficient 





















































































































As compared with control scrambled siRNA, all three GDA siRNAs significantly 
inhibited cell death and increased ASC speck formation and IL-1β secretion upon 
infection with C. trachomatis (Fig. 35A and 35B); IL-1β mRNA expression was 




Figure 34 GDA transcription levels in THP-1 GDA knockdown cells. GDA knock down verification. 





Figure 35 Knockdown of GDA in THP-1 and infection with C. trachomatis (A) LDH release and IL-
1β ELISA of THP-1 cells transfected with control or three different siRNAs against GDA. The cells were 
stimulated with IFNγ + LPS and infected with C. trachomatis at MOI 30 for 24 h, n=3; two-way ANOVA. 
(B) Quantification of inflammasome ASC specks in THP-1 transfected with 3 different GDA siRNAs, 
and infected with C. trachomatis at MOI 30 for 24 h, n=3; one-way ANOVA. (C) mRNA levels of IL-1β 
in THP-1 cells transfected with three different GDA siRNAs (n=3; one-way ANOVA. 
 
Notably, GDA knock down did not reduce bacterial growth, indicating that the impaired 
inflammasome activation is not an indirect effect of a lower bacterial load (Fig. 36). 
These results indicate that catabolism of GMP to uric acid via GDA and XO is required 


































































Figure 36 Number of inclusions in THP-1 GDA knockdown cells. Inclusion count of THP-1 cells 





4.6 hGBP1-produced GMP is metabolized to uric acid  
 
To verify this hypothesis, UA concentrations upon C. trachomatis infection in THP-1 
cells was measured. An infection-dependent increase of UA in parental cells as well 
as hGBP1 WT-expressing cells was observed, whereas hGBP1 KO cells, R48A 













Next, an antibody against UA was applied, which was originally generated for the 
diagnostics of rheumatic arthritis. A strong UA immunostaining around early C. 
trachomatis vacuoles as well as around mature inclusions was observed that spread 
throughout the cytoplasm (Fig. 38). UA staining was abolished in allopurinol-treated 
cells, confirming the specificity of the antibody (Fig. 38). UA has been associated with 



























































Figure 37 Relative increase of uric acid in THP-1 hGBP1 WT and mutant cell infected with C. 
trachomatis. Fold-change of UA concentrations in the cell culture supernatants of infected THP-1 cells 
vs. non-infected THP-1 cells. The cells were stimulated with IFN-γ + LPS and infected with C. 




















Previous studies have suggested that mitochondrial ROS increases downstream of 
UA production to activate NLRP3 inflammasome (Cruz et al., 2007). Consistently, an 
increase of mitochondrial ROS in C. trachomatis-infected cell was observed, which 
was abolished thereof by allopurinol treatment (Fig. 39). Thus, multiple lines of 
evidences support the conclusion that UA is produced upon C. trachomatis infection 























Figure 38 Uric acid staining in THP-1 cells infected with C. trachomatis and treated with 
allopurinol. THP-1 cells were stimulated with IFN-γ + LPS, infected with C. trachomatis at MOI 30, 
and treated with allopurinol or DMSO. Cells were stained for C. trachomatis (green), uric acid (red) and 




Figure 39 Production of mitochondrial ROS in THP-1 cells infected with C. trachomatis and 
treated with allopurinol. Fluorescence intensity measurements of mitochondrial ROS in THP-1 cells 
infected or not with C. trachomatis and treated or not with 500 µM allopurinol, n=3; two-way ANOVA. 
 
 
Lastly, it was tested whether infection-induced inflammasome activation could be 
rescued in hGBP1 KO cells and G68A mutants by feeding back intermediate 
metabolites of UA catabolism (Fig. 40A). As GTP itself is not cell permeable nor taken 
up by the cells directly, cells were alternatively treated with guanine or guanosine. 
Remarkably, the addition of guanine and guanosine to hGBP1 KO cells and G68A 
mutants to a dose-dependent increase of IL-1β secretion and pyroptosis (Fig. 40A-
40D). 





Figure 40 Rescue of inflammasome activation in hGBP1 KO and hGBP1 G68A THP-1 cells infected with C. 
trachomatis. (A) IL-1β ELISA and (B) LDH release of hGBP1 KO THP-1 cells, which were infected with C. 
trachomatis at MOI 30 for 24 h and treated with increasing concentrations of guanine or guanosine (0.5 mM and 1 
mM), n=3; statistical significance was determined in comparison to the parental cell line by two-way ANOVA. IL-1β 
ELISA (C) and LDH release (D) of hGBP1 WT or G68A mutant cells infected with C. trachomatis at MOI 30 for 24 
h and treated with increasing concentrations of guanine or guanosine (0.25 mM and 0.5 mM), n=3; significance 
was determined in comparison to the parental cells by two-way ANOVA 
 
 
In summary, these results indicate that hGBP1-mediated inflammasome activation 
occurs through consecutive cleavage of GTP to GMP, leading to local accumulation 
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In this study, a specific catalytic mutant of hGBP1 that retains cooperative GTP 
hydrolysis (i.e., at a comparable rate to the WT protein), while being impaired in the 
consecutive hydrolysis step, was generated. By employing this mutant, hGBP1’s 
unique function in GMP production using an infection model with the obligate 
intracellular pathogen C. trachomatis was explored. hGBP1 has been implicated in 
restricting pathogenic growth and mediating inflammasome activation. Furthermore, it 
was revealed that the GTPase activity of hGBP1 tightly coordinates these two 
functions. Thus, similar to other dynamin-related proteins, recruitment of hGBP1 to the 
PCV is thought to activate GTP hydrolysis, which may be linked to membrane 
remodeling and the destruction of the PCV (Daumke and Praefcke, 2016; Meunier et 
al., 2014). Ultimately, this work demonstrates that the succeeding second nucleotide 
cleavage step produced GMP, which then serves as a precursor of uric acid. In this 
scenario, the PCV acts as a platform that mediates the recruitment of hGBP1 and 
xanthine oxidase to the C. trachomatis inclusions to convert GMP to uric acid and 
initiate NLRP3 inflammasome signaling, leading to inflammatory cell death and the 
release of pro-inflammatory cytokines. In the following, the rationale of generating a 
specific GMP production mutant and its implication in previous and following studies, 
as well as the role of the first step of GTP hydrolysis in membrane remodeling and 
bacterial restriction will be discussed. Furthermore, novel insights into uric acid-
mediated NLRP3 inflammasome activation and future clinical implications of this work 
in treatment of C. trachomatis-induced inflammatory diseases will be elucidated. 
 
5.1 hGBP1 G68A – a specific GMP production mutant 
 
To date, the consecutive cleavage mechanism of hGBP1 has been studied 
extensively, offering novel insights into residues involved in binding and stabilizing all 
three nucleotides (GTP, GDP, GMP) as well as their transition states in the LG domain. 
However, the functional significance of this two-step cleavage mechanism in the 
restriction of intracellular pathogens is poorly understood and raises the demand for a 
specific mutation that impairs the GMP production while retaining the fast-cooperative 
WT-like kinetics. Mutation studies based on the consensus motifs (G1-G4) have 
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elucidated commonalities as well as differences between hGBP1 and other members 
of the dynamin superfamily and reveal that, similarly to human Atlastin-1, hGBP1 
employs a catalytic arginine finger (R48) that rearranges into a catalytically active state 
upon nucleotide binding and LG-domain dimerization. Mutation of this arginine residue 
does not prevent the protein from binding nucleotide and dimerization, but the mutant 
remains catalytically inactive. Thus, similarly to other dynamin superfamily proteins, 
mutations in the conserved switch regions of hGBP1 impair GTP hydrolysis (Ponten 
et al., 1997; Song et al., 2004).  
However, the biggest difference between hGBP1 and other members of the dynamin 
superfamily is the consecutive cleavage of GTP to GMP, where the two steps share 
the same cleavage mechanism via the same residues. This phenomenon renders the 
identification of residues specific to the second cleavage step a tremendous challenge. 
However, this special consecutive cleavage mechanism is based on the movement of 
the nucleotide within the binding pocket, placing the β-phosphate at the same position 
as the γ-phosphate. Therefore, point mutations for several glycine residues were 
designed that potentially sterically lock the movement of the nucleotide, suppressing 
the second cleavage step. Interestingly, among GBPs, GBP5 lacks the ability to cleave 
GTP to GMP but produces GDP instead. Most residues in the G motifs of the G domain 
are conserved between GBPs. Thus, whichever residues involved in enabling 
consecutive cleavage must differ between hGBP1 and hGBP5. G68 is located 
between the P-loop and switch I and is not conserved between dynamin superfamily 
members or GBPs. Crystal structures of hGBP1 reveal that it is in close proximity to 
the ribose moiety of the nucleotide and direct comparison of the amino acid sequence 
of GBP1 and GBP5 show that it is mutated to alanine. Therefore, G68 was a very good 
candidate for a point mutation to alanine that could specifically inhibit consecutive GTP 
hydrolysis. Indeed, mutation of G68 to alanine abolished GMP production while 





Figure 41 Residues of switch I of hGBP1 LG domain. Superimposition and magnification of hGBP1 
G-domain (switch I region) structures bound to GDP·AlFx (brown, pdb 2b 2) and GMP·AlFx (blue, pdb 
2b8w). Phosphate residues are colored in orange, oxygen atoms in red, nitrogen atoms in blue, Mg2+ 
as green ball and ALFx as green sticks. 
 
 
Previous work by Praefcke and colleagues identified residues H74 and L76 of switch 
I as GMP production mutants. GTP hydrolysis data reveals that mutants H74A and 
K76A retain cooperativity but exhibit impaired GMP production and significantly 
reduced GTP hydrolysis activity (Praefcke et al., 2004a). This study recapitulates 
these findings; however, the newly identified G68A mutant not only shows impaired 
GMP production but also retains a similarly high GTP hydrolysis activity. Interestingly, 
H74 and K76 are located in switch I in between residues T75 and S73, both of which 
are required for positioning a catalytic water molecule (see Fig. 42) (Ghosh et al., 
2006a). H74 and K76 contain large bulky side chains that can only be positioned in a 
restricted area within the tertiary structure of the LG-domain. When mutated to alanine, 
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the small CH3 side chain allows different conformations within its allocated space, 
indirectly permitting higher peptide backbone flexibility and perhaps flexible positioning 
of residues T75 or S73, thereby mildly impairing GTP hydrolysis. Further evidence 
underlining the hypothesis that residue K76 (and likely H74) is a mild GTP hydrolysis 
mutant is shown in Fig. 13D where at a given end point of GTP hydrolysis, WT hGBP1 
has hydrolyzed GTP to GMP and G68A hGBP1 has hydrolyzed GTP to GDP 




Figure 42 Sequence alignment of the G1-G4 motifs in GBP1, GBP2 and GBP5. G68 and A68 are indicated in 
red, S73 in purple, H74 in green, T75 in blue and K76 in orange 
 
 
Lastly, the design of the G68A mutant allows a clear assignment of the function of 
consecutive GTP hydrolysis. In this study, G68A mutant revealed that GMP production 
is not required for bacterial restriction. THP-1 cells expressing hGBP1 G68A were able 
to restrict C. trachomatis growth comparable to cells expressing the WT protein, 
whereas cells expressing K76A show partial impairment of bacterial restriction.  
According to these results, several studies that have referred to K76A or H74A as 
GMP production mutants need to be revisited and conclusions drawn from these 
experiments should be reevaluated. 
Taken together, the novel GMP production mutant hGBP1 G68A reveals, for the first 
time, that bacterial restriction is independent of the second hydrolysis step but is 




5.2 Membrane remodeling function, bacterial restriction and GTP hydrolysis 
by GBP1 
 
Although many studies suggest that GBPs are active on PCVs or pathogenic 
membranes, little is known about the nature of the membrane remodeling function. 
The closely related IRGs, which have been shown to target PCVs, can induce 
autophagy-dependent elimination and growth restriction of intracellular bacteria or 
direct PCV membrane destabilization (Haldar et al., 2013; Man et al., 2016; Petkova 
et al., 2013). A similar role has been suggested for GBPs, although several 
contradicting studies postulating mutually exclusive mechanisms of GBP action have 
been published (ref, ref, ref).  
Most studies focus on murine GBPs as genetic data is more accessible in vivo than 
for the human system. However, the lack of the perhaps functionally redundant IRGs 
in the human system suggests that human GBPs might fulfill a greater variety of 
functions. Common among the 11 murine GBPs and the 7 human GBPs is that GBP1, 
GBP2 and GBP5 exhibit a C-terminal CAAX motif and are thus isoprenylated. This 
allows these GBPs to target PCVs or the membrane of cytosolic bacteria and 
subsequently restrict the growth of pathogens (Kravets et al., 2012; Modiano et al., 
2005). How GBPs target pathogens or their vacuoles specifically remains unknown, 
as the PCV membrane consists of host lipids. A recent study implies that GBP1 binds 
LPS directly. Thus, GBP1 oligomerization was suggested to concentrate LPS, leading 
to disintegration of the bacterial membrane (Kutsch et al., 2020). This model potentially 
explains the mechanism of GBP-mediated inflammasome activation in response to 
cytosolic gram-negative bacteria. However, many studies show that GBPs not only 
target gram-negative bacteria, but also confer resistance to gram-positive bacteria and 
protozoa such as Mycobacterium bovis, Listeria monocytogenes and Toxoplasma 
gondii (Degrandi et al., 2013; Kim et al., 2011; Kravets et al., 2012; Shenoy et al., 
2012; Yamamoto et al., 2012). Furthermore, recombinantly expressed and 
farnesylated human GBP1 can bind many different lipids promiscuously in a 
nucleotide-dependent manner (Fres et al., 2010).  
In 2013, Al-Zeer and colleagues postulated that human GBP1 and GBP2 restrict C. 
trachomatis growth by mediating autophagosome fusion of inclusions and subsequent 
bacterial clearance from the host cell (Al-Zeer et al., 2013) . The hypothesis of a fusion 
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mechanism is also supported by structural similarities to Atlastin-1. Atlastin-1 is 
partially membrane-inserted due to its C-terminal transmembrane domain and 
dimerizes in a nucleotide-dependent manner, which leads to tethering of opposing ER 
membranes, ultimately mediating GTP hydrolysis-dependent membrane fusion (Hu et 
al., 2009; Orso et al., 2009). Fluorescence resonance energy transfer measurements 
with a soluble construct consisting of the GTPase domain and the helical bundle 
revealed the movements of these domains during nucleotide hydrolysis (Byrnes et al., 
2013). Also, crystal structures of the Atlastin-1 dimer showed two profoundly different 
conformations of the helical domain relative to the GTPase domains in the GMPPNP 
and GDP‐bound state. The GDP‐bound form embodies the open conformation with 
the two GTPase domains facing each other and the helical domains protruding from 
the GTPase dimer in opposite directions. The second structure features Atlastin-1 
bound to GMPPNP, in which the helical domains extend in parallel directions and 






Figure 43 Conformational changes of Atlastin-1 upon GTP hydrolysis. Structure of atlastin in the (A) 
GMPPNP‐ (pdb 4IDP) and (B) GDP‐bound forms (3Q5E). 
 
Biochemical and structural studies of hGBP1 reveal a tight intramolecular interaction 
between the C-terminal α6/6’ helices and the N-terminal LG-domain that is only 
released upon GTP hydrolysis, leading to major rearrangement of the helical domain 
(Vöpel et al., 2010). Furthermore, in vitro farnesylated hGBP1 can assemble into large 
ring-shaped oligomers in the presence of the transition state mimic GDP ALFx that can 
oligomerize into rod-shaped ring polymers in the presence of GTP. These rings do not 
form in the presence of the slowly hydrolyzing GTP-analog GTPγS, indicating that 
GTP hydrolysis is required for the formation of rings. Biochemical assays show that 
farnesylated hGBP1 can tether giant unilamellar vesicles (GUVs) in the presence of 
GTP and GTPγS. Where binding to GTPγS lead to a stable attachment of two vesicles 
and the presence of GTP allowed for repetition of short-lived hemi-fusion events 
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(Shydlovskyi et al., 2017). However, the significance of the second hydrolysis step for 
these events have remained unknown. Results of this thesis reveal that the GMP 
production mutant hGBP1 G68A can bind Folch liposomes and form an oligomeric 
ring structure in the presence of GDP AlFx (see Fig. 16), but the functionality of this 
mutant in tethering GUVs has not been tested. The ability of THP-1 cells expressing 
hGBP1 G68A to restrict the growth of C. trachomatis with similar efficiency as the WT 
protein would suggest, that GMP production is not required for hemi-fusion of GUVs 
or any membrane remodeling event of hGBP1 that is significant in vivo. In contrast, 
other studies indicate that GBPs might lyse PCVs or bacterial membranes. Arguably, 
Salmonella PCVs that stain positive for GBPs, also are stained positive for galectin-8, 
a protein known to bind β-galactins of the inner leaflet of the PCV membrane, 
indicating that a PCV membrane rupture must have occurred. Also, more cytosolic 
Salmonella were found in WT BMDMs compared to GBPchr3 KO, suggesting that more 
salmonella escape the PCV in the presence of GBPs (Pilla et al., 2014). Additional 
studies demonstrate PCV lysis of the parasite Toxoplasma gondii in BMDM and MEF 
cells (Kravets et al., 2016). However, later studies with Francisella novidica and 
Legionella pneumophila indicate that GBP- dependent bacteriolysis occurs after PCV 
rupture (Liu et al., 2018; Man et al., 2015; Meunier et al., 2014; Meunier et al., 2015). 
Most studies share the consensus that GBPs liberate PAMPs of pathogens that can 
be subsequently sensed by either canonical or non-conical inflammasomes, 
supporting a lysis mechanism. However, studies of the murine pathogen C. muridarum 
suggest that inflammasome activation occurs independently of membrane targeting 
by GBPs, as GBPs do not localize to C. muridarum inclusions but can still activate the 
NLRP3 inflammasome (Finethy et al., 2015). In summary, the results of this thesis 
suggest that GBP-mediated bacterial restriction based on membrane remodeling 
occurs independent of the second hydrolysis step of GTP. Clearly, further investigation 





5.3 GBPs in the activation of inflammasome and cell death pathways  
 
Murine and human GBPs have been demonstrated to activate a plethora of 
inflammasome and cell death pathways. Except for C. muridarum, mouse GBPs can 
localize to PCVs or bacterial membranes, which is followed by PCV or bacteriolysis by 
a so far unknown mechanism. Subsequently, bacterial PAMPs such as LPS are 
released that can be sensed by caspase 11 (caspase-4/5 in human) and leads to the 
cleavage and activation of gasdermin-D, a pore forming protein that translocates to 
the plasma membrane and causes pyroptosis (Kayagaki et al., 2015; Lagrange et al., 
2018; Meunier et al., 2014; Pilla et al., 2014). Another PAMP that is released into the 
cytosol is bacterial DNA, which can lead to the activation of the canonical AIM2 
inflammsome in response to Francisella novidica infection (Meunier et al., 2015). In 
the case of C. muridarum where inclusion localization is not detected or C. 
trachomatis, GbpChr3 mediate activation of the canonical NLRP3 or AIM2 
inflammasome (Finethy et al., 2015). Also, mouse GBP5 is proposed to be involved in 
the activation of the canonical inflammasome pathway during infection with the gram-
positive bacterium L. monocytogenes (Shenoy et al., 2012). Human GBPs have been 
shown to localize to the C. trachomatis inclusion, S. typhimurium vacuole and to the 
outer membrane of Shigella flexneri (Al-Zeer et al., 2013; Meunier et al., 2014). hGBP1 
has been demonstrated to promote caspase-4 dependent pyroptosis in response to 
S. typhimurium infection (Santos et al., 2020) and hGBP2 in response to F. novidica 
infection (Lagrange et al., 2018). Human GBP1 can not only promote inflammatory 
cell death but also apoptosis during Toxoplasma gondii infection over AIM2 and 
caspase-8 activation (Fisch et al., 2019). Recent studies suggest that direct binding of 
LPS by GBP1 leads to the activation of the non-canonical inflammasome either 
through LPS dependent bacteriolysis or subsequent recruitment of other GBPs to form 
an activation platform for caspase-4 in response to Shigella and Salmonella infection 
(Kutsch et al., 2020; Santos et al., 2020). However, there is no consensus between 
the studies, which specific LPS antigen is involved or whether nucleotide is necessary 
for LPS binding. In this work, human GBP1 was shown to mediate canonical NLRP3 
activation during C. trachomatis infection through consecutive GTP hydrolysis in a 
mechanism independent of bacterial restriction. The consensus among all studies is 
that GBPs restrict pathogenic growth within the host cell and mediate inflammasome 
activation. Yet, the existence of one common mechanism to explain these key 
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functions is rather unlikely. Moreover, it seems that the inflammasome pathway 
activated is specific to the pathogen invading the host cell, rendering GBPs flexible 
and versatile factors in antimicrobial defense. Since several independent effector 
mechanism of GBPs appear to exist, it would be intriguing to test the newly generated 
GMP production mutant in the context of different infection models and further dissect 




5.4 Uric acid as a NLRP3 activator 
 
Uric acid is the main product of purine catabolism and is regularly secreted in urine 
(Maesaka and Fishbane, 1998). Compared to other organisms, higher apes and 
humans lack an enzyme called uricase that oxidizes uric acid to 5-hydroxyisourate 
that can spontaneously dissociate into allantoin and water. Therefore, uric acid levels 
in humans are several times higher than in other organisms (Oda et al., 2002). 
Accumulation of uric acid can lead to crystal formation, a DAMP released from 
deoxygenated tissues and dying cells (Shi et al., 2003). This DAMP can activate the 
immune system as it leads to an increase in ROS, decrease in nitric oxide, activates 
chemotaxes, induces pro-inflammatory signaling pathways and triggers the 
expression of pro-inflammatory cytokines (Di Giovine et al., 1987; Martinon et al., 
2006b; So and Thorens, 2010). Besides uric acid, silica and cholesterol crystals are 
known to induce inflammasome activation (Dostert et al., 2008; Duewell et al., 2010; 
Hornung et al., 2008), by causing lysosomal damage and the release of lysosomal 
content into the cytosol (Lima et al., 2013). Lysosomal proteases can damage vital 
proteins in the cytosol and affect other organelles such as mitochondria, which leads 
to an increase in mitochondrial ROS (mtROS) production (Schaefer, 2014), release of 
oxidized mitochondrial DNA and NLRP3 inflammasome activation (Shimada et al., 
2012b). Uric acid crystals can also directly interact with membranes and activate 
potassium-ion (K+) efflux, suggesting the convergence of many NLRP3 activating 
pathways (Mariathasan et al., 2006). Recent studies reveal that serum uric acid levels 
are associated with inflammatory diseases such as gout-related disease and 
preeclampsia (Acauan Filho et al., 2016; Crișan et al., 2016) and soluble uric acid can 
activate the NLRP3 inflammasome in a mtROS dependent manner (Braga et al., 
2017). Elevated uric acid levels are often associated with purine-rich diets of modern 





Figure 44 NLRP3 activation by uric acid. Uric acid accumulates as a degradation product of GMP produced by 
hGBP1. Uric acid crystals can stimulate NLRP3 activation by inducing mitochondrial or lysosomal damage, leading 
to the release of mitochondrial DNA (mtDNA), mitochondrial ROS (mtROS) or cathepsin. Uric acid also induces K+ 
Efflux that is a NLRP3 activating DAMP. 
 
Results in this thesis indicate that uric acid accumulates in cells infected with C. 
trachomatis and that this accumulation is a direct cause of GBP1-mediated GMP 
production. THP-1 cells that do not express GBP1 or GTP hydrolysis mutants lead to 
lower levels of uric acid and impaired NLRP3 inflammasome activation. The results 
further demonstrate that the succeeding second nucleotide cleavage step by GBP1 
produces GMP, which then serves as a precursor of uric acid. In this scenario, the 
PCV acts as a platform that mediates the recruitment of hGBP1 and xanthine oxidase 
to the C. trachomatis inclusions to initiate inflammasome signaling. At the same time, 
C. trachomatis infection leads to an increase in GDA expression (Fig. 30). Thus far, it 
has been unclear whether this regulation of nucleotide metabolizing enzymes is 
merely part of a host defense mechanism or a way of C. trachomatis to redirect the 
85 
 
host metabolism as part of a survival strategy. Downregulation of GDA did not affect 
pathogenic growth, suggesting that GDA activity and UA formation are not required 
for survival of C. trachomatis under regular conditions. However, loss of hGBP1-
mediated GMP production reduced C. trachomatis-induced cell death, implying a 
direct link between guanine catabolism and inflammasome activation. Although a 
contribution of hGBP2 to C. trachomatis-dependent UA formation was ruled out, it 
cannot be excluded for other hGBPs that execute the second hydrolysis step. Another 
recent study indicates that uric acid crystals form during infection of enteropathogenic 
Escherichia coli (EPEC) and Shiga-toxic E.coli (STEC) in the gastrointestinal tract 
(Crane et al., 2016). Although the physical state of uric acid that triggers NLPR3 
inflammasome activation has not been addressed in this thesis, staining data with an 
antibody that detects uric acid crystals as an epitope indicate that uric acid crystals 
accumulate in THP-1 macrophages upon C. trachomatis infection. Furthermore, 
mtROS is produced during C. trachomatis infection that can be reduced with an 
inhibitor of the nucleotide-uric acid catabolism pathway, suggesting that NLRP3 
activation occurs in a mtROS-dependent manner caused by uric acid crystal formation. 
Interestingly, intracellular levels of uric acid in THP-1 cells did not differ between non-
infected and infected cells. In fact, differences in uric acid levels were only detected in 
the low-serum medium supernatant upon infection, suggesting that uric acid is 
secreted rapidly, when accumulated. While treatment with NLRP3 inhibitor MCC950 
did significantly reduce pyroptosis, it did not lead to better detection of intracellular uric 
acid levels. Therefore, extracellular accumulation of uric acid may occur through direct 




Figure 45 Model for hGBP1-mediated NLRP3 inflammasome activation during C. trachomatis infection. 
Upon C. trachomatis infection, hGBP1 is recruited to the Chlamydia inclusion and oligomerizes on the inclusion 
membrane. C. trachomatis infection leads to the upregulation of GDA expression and recruitment of XO to the 
inclusion membrane. GMP produced by hGBP1 is catabolized to uric acid in a specialized pipeline. Uric acid leads 
to NLRP3 activation. 
 
 
In summary, this study describes a novel model of canonical inflammasome activation 
through GBP1 in response to C. trachomatis infection. In this scenario, GBP1 
produces GMP that is rapidly converted into the danger signal uric acid, which in turn 
activates the NLRP3 inflammasome leading to cytokine release and pyroptosis. In the 
future, it might be useful to test whether inflammasome activation is triggered via the 






5.5 Future implications of allopurinol in the treatment of C. trachomatis 
infection induced acute inflammation  
 
While GBPs have been associated with inflammasome activation in response to 
infection with C. trachomatis and other intracellular pathogen, the mechanism of GBP-
mediated inflammasome activation was unclear. Results of this thesis demonstrate 
that NLRP3 inflammasome activation occurs through GBP1-mediated GMP 
production that is further catabolized to uric acid. Inhibition of the catabolism of GMP 
to uric acid by gene silencing of GDA leads to impaired NLRP3 inflammasome 
activation, cytokine release and pyroptosis. Treatment with the clinically approved XO 
inhibitor allopurinol showed the same effects in a dose-dependent manner in THP-1 
cells. Additionally, allopurinol leads to reduction of C. trachomatis infection induced 
mtROS generation in THP-1 cells, suggesting that increase in mtROS is directly 
dependent on uric acid production. As an obligate intracellular pathogen, C. 
trachomatis cannot synthesize purines or pyrimidines and depends on the host cell for 
these metabolites (Tipples and McClarty, 1993). However, neither reduction of the 
GDA protein level nor treatment with allopurinol significantly reduced the number of C. 
trachomatis inclusions in THP-1 24 h post infection. A possible explanation for this 
phenomenon is, that other purine and pyrimidines could be acquired by 
interconversion of intermediate metabolites in the pathway. Although the immediate 
growth of C. trachomatis was not affected, the influence of the inhibition of nucleotide 
catabolism pathways during further development of the infectious progeny has not 
been tested. Mouse macrophages utilize multiple inflammasome pathways in 
response to C. trachomatis infection (Finethy et al., 2015). Conversely, results of this 
thesis indicate that the uric acid-NLRP3 axis is mainly responsible for the host 
response to C. trachomatis infections in humans. Furthermore, the data suggest that 
inflammasome activation in human macrophages in response to C. trachomatis 
infection is rather independent of PAMP liberation by hGBPs, substantiating the finding 
that inflammation occurs over a unified pathway. Therefore, allopurinol could be a 
potential therapeutic application in reducing acute inflammation in patients suffering 
from C. trachomatis infection. Thus far, allopurinol has been applied in the treatment 
of acute gout to reduce the accumulation of uric acid crystals in joints and reduce acute 
inflammation (Hitchings and Elion, 1963; Pacher et al., 2006). However, it would be 
intriguing to test whether inflammasome activation is triggered via the same pathway 
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in response to other intracellular pathogen and could be acutely treated with 





Human guanylate binding protein 1 (hGBP1) belongs to the dynamin superfamily of 
GTPases and conveys host defense against intracellular bacteria and parasites. 
During infection, hGBP1 is recruited to pathogen-containing vacuoles, such as 
Chlamydia trachomatis inclusions, restricts pathogenic growth, and induces the 
activation of the inflammasome pathway. hGBP1 has a unique catalytic activity to 
hydrolyze GTP to GMP in two consecutive cleavage steps. However, the functional 
significance of this activity in host defense remains elusive. In this thesis, a structure-
guided mutant that specifically abrogates GMP production, while maintaining fast 
cooperative GTP hydrolysis, was generated. Complementation experiments in human 
monocytes/macrophages show that hGBP1-mediated GMP production is dispensable 
for restricting Chlamydia trachomatis growth but is required for inflammasome 
activation. Mechanistically, GMP is catabolized to uric acid, which in turn activates the 
NLRP3 inflammasome via induction of mitochondrial ROS. Our study demonstrates 







Das zur Dynamin-Superfamilie gehörende humane Guanylate Binding Protein 1 
(hGBP1) ist für die zelluläre Immunabwehr gegen Bakterien und Parasiten 
verantwortlich. Bei einer Infektion wird hGBP1 zu bakteriellen Vakuolen, z.B. 
Chlamydia trachomatis Inklusionen, rekrutiert, wodurch es zur Restriktion des 
bakteriellen Wachstums kommt. Zudem trägt hGBP1 zur Aktivierung des 
Inflammasoms bei. hGBP1 hat einen einzigartigen katalytischen Mechanismus, durch 
den es GTP zu GMP in zwei aufeinander folgenden Stufen hydrolysieren kann. Die 
funktionelle Relevanz dieses Mechanismus in der bakteriellen Abwehr ist allerdings 
noch nicht erforscht.  
In dieser Doktorarbeit wurde diese Frage mit Hilfe einer Kristallstruktur-basierten 
Mutante erforscht. Diese Mutante hydrolysierte GTP nur noch zu GDP, dies aber mit 
derselben kooperativen Aktivität wie der Wildtyp. Die Funktionalität dieser Mutante 
wurde mit Hilfe von Komplementationsexperimenten in humanen Monozyten und 
Makrophagen ermittelt. Die Ergebnisse zeigen, dass GMP Produktion durch hGBP1 
nicht notwendig für die Restriktion bakteriellen Wachstums ist. Stattdessen ist der 
zweite Hydrolyse-Schritt für die Aktivierung des NLRP3 Inflammasoms wichtig. 
Hierbei wird das von hGBP1 produzierte GMP zur Harnsäure umgesetzt, welches das 
NLRP3 Inflammasom durch mitochondrialen reaktiven Sauerstoff aktiviert. Diese 
Doktorarbeit zeigt daher auf, wie hGBP1 die Restriktion bakteriellen Wachstums und 
die Inflammasom Aktivierung durch seinen einzigartigen enzymatischen 
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Appendix B-List of instruments 
 
Instruments Manufacturer 
Agarose Gel Electrophoresis System Biometra Göttingen D 
Äkta FPLC OLS,Bremen D 
Äkta Prime Plus Invitrogen, Darmstadt D 
Äkta Purifier Biorad, Hercules, USA 
Amicon centrifugal filter devices Millipore, Billersica, USA 
Benchtop Centrifuge 5415 D Eppendorf, Hamburg, D 
Benchtop Centrifuge 5415 R Thermofisher Scientific, Dreiech, D 
Benchtop Centrifuge 5804 R Eppendorf, Hamburg, D 
Butyl Sepharose 4B Fast Flow GE Healthcare, Piscataway, USA 
Cell culture flasks Eppendorf, Hamburg, D 
Cell culture plates  Eppendorf, Hamburg, D 
Centrifuge Avanti J-26 XP Pneumatic Microfluidics, Newton, USA 
Chromotography column GST HP 1 mL Beckman Coulter, Krefeld, D 
Chromotography column HisTrap 1 mL Beckman Coulter, Krefeld, D 
Chromotography column material GSH 
Sepharose 4B 
Beckman Coulter, Krefeld, D 
Chromotography column Ni Sepharose 
HP 
GE Healthcare, Piscataway, USA 
Chromotography column Superdex 200 
16/60,10/300 
GE Healthcare, Piscataway, USA 
Epoch2 microplate reater GE Healthcare, Piscataway, USA 
Fluidizer M-110L GE Healthcare, Piscataway, USA 
Heracell 150 cell culture incubator GE Healthcare, Piscataway, USA 
HPLC Infinity Ismatec, Glattbrug, CH 
Hypersil ODS guard column GE Healthcare, Piscataway, USA 
Peristaltic Pump Reglo Analog ISM827B GE Healthcare, Piscataway, USA 
pH-Meter GE Healthcare, Piscataway, USA 
Photometer BioPhotometer Agilent Technologies, Santa Clara, USA 
Photometer NanoDrop 2000 Agilent Technologies, Santa Clara, USA 
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Reversed-phase ODS-2 Hypersil HLPC 
column 
Thermofisher Scientific, Dreiech, D 
Scales Mettler-Toledo, Giessen, D 
SDS OAGE System Xcell sure Lock Satorius, Göttingen, D 
Shaker incubator Innova44 New Brunswick Scientific, Edison, USA 
Synergy H1 plate fluorescence 
microplate reader 
TPP, Trasadingen, CH 
Thermocycler TGradient  TPP, Trasadingen, CH 
Ultracentrifuge Optima L-100K Biotek, Winooski, USA 
Ultracentrifuge Optima TLX Biotek, Winooski, USA 
Western blot system Corning®, corning,USA 
White, polystyrene medium binding 96-
well ELISA plates 
Carl Zeiss, Oberkochen, D 
Zeiss EM910 Carl Zeiss, Oberkochen, D 
ZEISS LSM 700 Confocal Laser 
Scanning Microscope 
Carl Zeiss, Oberkochen, D 




Appendix C-List of Chemicals 
 
Chemical Catalog number Manufacturer 
2-Log DNA ladder N3200S NEB, Frankfurt a.M., D 
Acetic acid 3783.5 Roth, Karlsruhe, D 
Acetone 9372.2 Roth, Karlsruhe, D 
Acetonitrile CN20.2 Roth, Karlsruhe, D 
Agarose 2267.3 Roth, Karlsruhe, D 
Allopurinol 10012597 
Cayman Chemical 
Company, Ann Arbor, USA 
Aluminum chloride 563919 Sigma-Aldrich, Steinheim. D 
Bafilomycin A1 ab120497 Abcam,UK 
carbenicillin disodium salt 6344.2 Roth, Karlsruhe, D  
Coomassie brilliant blue R 250 3862.2 Roth, Karlsruhe, D 
DTT 6908.2 Roth, Karlsruhe, D 
EDTA 8040.2 Roth, Karlsruhe, D 
Ethanol 5054.2 Roth, Karlsruhe, D 
Ethidium bromide 2218.1 Roth, Karlsruhe, D 
Ferrostatin-1 A13247 
Adooq Bioscience, Irvine, 
USA 
Fetal bovine serum A11,211 PAA laboratories 




Glutathione Sepharose 4B 27-4574-01 Amersham,Piscatawy,USA 
Glycerol 3783.1 Roth, Karlsruhe, D 
GSH reduced 3541 Calbiochem, Darmstadt, D 
GTP NU-1012-1G Jena Bioscience, D 
Guanidinehydrochloride 37.1 Roth, Karlsruhe,D 
HEPES 9105.4 Roth, Karlstuhe, D 
Horse serum 26050088 
Gibco/Thermofisher 
Scientific, Dreiech, D 
Human recombinant IFN-γ IF002 Merck Millipore 
Human recombinant M-CSF M6518 Sigma-Aldrich,Steinheim,D 
IM54 13323 
Cayman Chemical 
Company, Ann Arbor, USA 
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Imidazole 3899.3 Roth, Karlsruhe, D 
Isopropanol 9866.5 Roth, Karlsruhe, D 
Isopropyl-β-D-
thiogalactopyranosid 
2316.5 Roth, Karlsruhe, D 
Kanamycinsulfate T823.4 Roth, Karlsruhe, D 
LPS, E. Coli O111:B4 LPS25 
Merck Millipore, Burlington, 
USA 
Magnesium chloride Hexahydrate 63065 Sigma-Aldrich, Steinheim, D 
Mark12 unstained standard LC5677 









Ni Sepharose HP 71-5027-67 AD Ge Healthcare, München 
NuPAGE LDS Sample Buffer NP0007 
Life Technologies, 
Karlsruhe, D 
NuPAGE MES SDS Buffer NP0060 
Life Technologies, 
Karlsruhe, D 
NuPAGE MOPS SDS Buffer NP0050 
Life Technologies, 
Karlsruhe, D 




Phorbol 12-Myristate 13-Acetate 524400 Sigma-Aldrich, Steinheim, D 
PMSF 6367.4 Roth, Karlsruhe, D 
Poly (dA:dT) P0883-10UN Sigma-Aldrich, Steinheim, D 
Sodium chloride 9265.2 Roth, Karlsruhe, D 
Western blot detection reagent 
ECL 
RPN2232 
Amersham, GE healthcare, 
München 





Appendix D - List of Enzymes 
 
Enzyme Manufacturer 
DNase I NEB, Frankfurt a.M., D 
T4 DNA Ligase NEB, Frankfurt a.M., D 
T4 Polynucleotide kinase  NEB, Frankfurt a.M., D 





Appendix E-List of Kits 
 
Kits Manufacturer 
Plasmid Mini Prep Kit Jena Bioscience, Jena,D 
Plasmid Midi Prep Kit QIAGEN, Hilden, D 
CytoTox-ONE™ Homogeneous Membrane 
Integrity Assay 
Promega, Walldorf, D 
Uric Acid/Uricase Assay kit Cell Biolabs, inc., San Diego, USA 
MitoSOX™ Red Mitochondrial Superoxide 
Indicator 
Thermo Fisher Scientific, Dreeich, D 
Human IL-1 beta/IL-1F2 DuoSet ELISA kit R&D Biosystems, Wiesbaden, D 
FuGENE® HD Transfection Reagent Promega, Walldorf, D 
Profect-P1-lipid based protein delivery 
reagent 
Targeting Systems, El Cajon, USA 
Lipofectamine™ RNAiMAX Transfection 
Reagent 
Thermo Fisher Scientific, Dreiech, D 
SYBR green qPCR mastermix Thermofisher Scientific, Dreiech, D 
KOD Hot Start polymerase Kit Merck Millipore, Darmstadt, D 





Appendix F-List of Media 
 
Medium Manufacturer 
Terrific Borth (TB) Roth, Karlsruhe, D 
DMEM Gibco/Thermofisher Scientific, Dreiech, D 
RPMI 1640 Gibco/Thermofisher Scientific, Dreiech, D 
Opti-MEM Gibco/Thermofisher Scientific, Dreiech, D 





Appendix G-List of Buffers 
 
Buffer Components 
Resuspension buffer 50 mM Tris–HCl (pH 8.0), 5 mM MgCl2, 
300 mM NaCl, 5 mM β-mercaptoethanol, 
10% (v/v) glycerol, 20 mM imidazole, 100 
µM phenylmethylsulfonyl fluoride 
(PMSF), 1 µg/mL DNase I 
Equilibration buffer 50 mM Tris–HCl (pH 8.0), 5 mM MgCl2, 
300 mM NaCl, 5 mM β-mercaptoethanol, 
10% (v/v) glycerol, 20 mM imidazole, 
Washing buffer 50 mM Tris–HCl (pH 8.0), 5 mM MgCl2, 
500 mM NaCl, 5 mM β-mercaptoethanol, 
10% (v/v) glycerol, 20 mM imidazole, 
Dialysis buffer 50 mM HEPES pH 7.5, 150 mM NaCl, 5 
mM MgCl2 and 2 mM dithiothreitol 
Elution buffer 50 mM Tris–HCl (pH 8.0), 5 mM MgCl2, 
500 mM NaCl, 5 mM β-mercaptoethanol, 
10% (v/v) glycerol, 20 mM imidazole, 
SEC buffer 50 mM HEPES pH 7.5, 150 mM NaCl, 5 
mM MgCl2 and 2 mM dithiothreitol 
Hydrophobic gradien buffer A 50 mM Tris-HCl, pH 8.0, 2 mM MgCl2, 2 
mM DTT, 1.5 mM (NH4)2SO4 
Hydrophobic gradien buffer B 50 mM Tris-HCl, pH 8.0, 2 mM MgCl2, 2 
mM DTT,  
Liposome buffer 25 mM HEPES, pH 7.5, 150 mM NaCl 
and 1 mM MgCl2 
GTPase buffer 20 mM HEPES pH 7.5, 150 mM NaCl, 2 
mM MgCl2  
GDP·AlFx complex formation buffer 20 mM HEPES pH 7.5, 150 mM NaCl, 2 
mM MgCl2, 200 µM GDP, 300 µM AlF3 
and 10 mM NaF 
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HPLC buffer 100 mM potassium phosphate buffer pH 6.5, 






Appendix H - List of Constructs 
 
Protein Mutation Species Plasmid 
hGBP1 N/A Homo sapiens pSKB-LNB2 
hGBP1  G68A Homo sapiens pSKB-LNB2 
hGBP1  R48A Homo sapiens pSKB-LNB2 
hGBP1  K76A Homo sapiens pSKB-LNB2 
hGBP1 N/A Homo sapiens pCMV-GFP Hygro 
hGBP1  G68A Homo sapiens pCMV-GFP Hygro 
hGBP1  R48A Homo sapiens pCMV-GFP Hygro 
hGBP1  K76A Homo sapiens pCMV-GFP Hygro 
hGBP1  CRISPR KO 
sgRNA1 
Homo sapiens plenti-CRISPR-V2 
hGBP1  CRISPR KO 
sgRNA2 





Appendix I - List of Abbreviations 
 
Abbreviation meaning 
APC antigen presenting cell 
ASC adaptor molecule apoptosis-associate speck-like protein containing a caspase 
recruitment domain  
CARD caspase activation and recruitment domain  
CRISPR Clustered Regularly Interspaced Short Palindromic Repeat 
DAMP danger-associated molecular pattern 
EB elementary bodies 
ELISA enzyme-linked immunosorbant assay 
EPEC enteropathogenic E. coli 
ERK extracellular signal-regulated kinases  
GBP guanylate binding protein 
GbpChr3 gbp genes on mouse chromosome 3 
GDA guanine deaminase 
IAP baculoviral inhibitor of apoptosis  
IFIT1 interferon- induced protein with tetratricopeptide repeats 1  
IFNGR IFN-γ receptor  
IFN-γ Interferon-γ  
IKKβ inhibitor of nuclear factor kappa-B kinase subunit beta  
IL Interleukin 
IL1R1 IL-1β type 1 receptor  
IL-1RAP IL-1 receptor accessory protein  
Inc inclusion membrane protein 
IRAK4 IL-1 receptor-associated kinase 
IRF3 interferon regulatory factor 3 
IRG immune related GTPase 
ISG interferon stimulated gene 
IκB nuclear factor kappa-B inhibitor  
JAK Janus kinase 
JNK c-Jun N-terminal kinases  
LDH lactate dehydrogenase 
LG large GTPase 
LPS lipopolysaccharides 
LRR leucine rich repeat  
MAP2K mitogen-activated protein kinase kinase  
MAP3K mitogen-activated protein kinase kinase kinase 
MAPK mitogen-activated protein kinase 
MOMP major outer membrane protein  
MTOC microtubule organizing center 
MYD88 myeloid differentiation primary response gene 88  
NACHT NAIP (neuronal apoptosis inhibitory protein), CIITA (MHC class II transcription 
activator), HET-E (incompatibility locus protein from Podospora anserina) and 
TP1 (telomerase-associated protein) 
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Nek7 NIMA-related kinase 7  
NF-κB  nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NLR NOD-like receptor 
NOS nitric oxide synthase 
PAMP pathogen-associated molecular pattern 
PCV pathogen containing vacuole  
PRR pattern recognition receptor  
PYD Pyrin domain 
RB reticulate bodies 
ROS reactive oxygen species  
STAT signal transducer and activator of transcription 
STEC Shiga-toxic E. coli 
STING synthase stimulator of interferon genes 
TAB TAK1-binding proteins  
TAK TGF-β-activated kinase  
TIR Toll- and IL-1R–like  
TLR toll-like receptor 
TNF tumor necrosis factor  
TNF-α tumor necrosis factor α   
TOLLIP Toll-interacting protein  
TRAF tumor necrosis factor-associated factor 
TRAM TRIF-related adapter molecule  
TRIF TIR-domain-containing adapter-inducing interferon-β  
UA uric acid 
VLIG very large inducible GTPases 
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